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Abstract
Macrophage nitric oxide (NO) production and hypoxia coexist during wound healing, and have been
implicated in the pathogenesis and pathophysiology of multiple disease states including sepsis and cancer.
Macrophages stimulated with pathogen associated molecular patterns (PAMPs) produce NO via inducible
nitric oxide synthase (iNOS) from molecular O2, L-arginine, and NADPH. The first aim of this research was
to characterize the degree and duration of hypoxia which would limit NO production by PAMPs stimulated
macrophages. The second aim was to identify the contributing mechanism(s). Using a novel forced
convection cell culture system, we demonstrated that NO production was rapidly (within seconds) and
reversibly regulated by physiological and pathophysiological O2 tensions (pO2). The effect of pO2 on NO
production was not mediated by changes in iNOS protein concentration or iNOS dimerization, implicating
limitation of the reactant(s) as the predominant causative mechanism. In addition to O2 limitation, hypoxia
has the potential to affect NADPH and L-arginine availability. In PAMPs stimulated macrophages, NADPH is
predominantly produced by the oxidative pentose phosphate cycle (OPPC). NO production directly
correlated with OPPC activity over a wide range of pO2, and inhibition of NO production with the specific
iNOS inhibitor, 1400W, significantly decreased OPPC activity. OPPC activity increased significantly in
response to chemically mediated oxidative stress irrespective of pO2, and NO production was unaffected by
increasing cellular oxidative stress, indicating that NADPH availability for NO production was not limited by
hypoxia. L-arginine is required for iNOS dimerization, and iNOS dimerization was maintained or increased
during hypoxic exposure, suggesting sufficient L-arginine was available. Furthermore, the effect of L-arginine
depletion on NO production was much slower than the response observed due to changes in pO2. In
conclusion, decreased O2 availability is the predominant mechanism responsible for rapidly and reversibly
limiting NO production by PAMPs stimulated macrophages exposed to acute hypoxia.
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ABSTRACT 
CHAGES IN OXYGEN TENSION RAPIDLY AND REVERSIBLY REGULATE 
MACROPHAGE NITRIC OXIDE PRODUCTION 
Mary A. Robinson 
Advisors: Cynthia M. Otto and Cameron J. Koch 
 
Macrophage nitric oxide (NO) production and hypoxia coexist during wound 
healing, and have been implicated in the pathogenesis and pathophysiology of multiple 
disease states including sepsis and cancer.  Macrophages stimulated with pathogen 
associated molecular patterns (PAMPs) produce NO via inducible nitric oxide synthase 
(iNOS) from molecular O2, L-arginine, and NADPH.  The first aim of this research was 
to characterize the degree and duration of hypoxia which would limit NO production by 
PAMPs stimulated macrophages.  The second aim was to identify the contributing 
mechanism(s).  Using a novel forced convection cell culture system, we demonstrated 
that NO production was rapidly (within seconds) and reversibly regulated by 
physiological and pathophysiological O2 tensions (pO2).  The effect of pO2 on NO 
production was not mediated by changes in iNOS protein concentration or iNOS 
dimerization, implicating limitation of the reactant(s) as the predominant causative 
mechanism.  In addition to O2 limitation, hypoxia has the potential to affect NADPH and 
L-arginine availability.  In PAMPs stimulated macrophages, NADPH is predominantly 
produced by the oxidative pentose phosphate cycle (OPPC).  NO production directly 
correlated with OPPC activity over a wide range of pO2, and inhibition of NO production 
with the specific iNOS inhibitor, 1400W, significantly decreased OPPC activity.  OPPC 
activity increased significantly in response to chemically mediated oxidative stress 
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irrespective of pO2, and NO production was unaffected by increasing cellular oxidative 
stress, indicating that NADPH availability for NO production was not limited by hypoxia.  
L-arginine is required for iNOS dimerization, and iNOS dimerization was maintained or 
increased during hypoxic exposure, suggesting sufficient L-arginine was available.  
Furthermore, the effect of L-arginine depletion on NO production was much slower than 
the response observed due to changes in pO2.  In conclusion, decreased O2 availability is 
the predominant mechanism responsible for rapidly and reversibly limiting NO 
production by PAMPs stimulated macrophages exposed to acute hypoxia. 
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INTRODUCTION
Macrophage NO Production
Macrophages are found throughout vertebrate and invertebrate tissues at all stages 
of life.  They mediate tissue development and maintenance, and innate (pathogen pattern 
recognition) and adaptive (antigen presentation to T cells) immunity, but are also 
implicated in many disease states (208).  The mononuclear phagocytic system classifies 
adult vertebrate macrophages based on their tissue phenotype and currently includes: 
inflammatory macrophages (M1 macrophages, aka classically activated macrophages), 
alternatively activated macrophages (M2 macrophages), dendritic cells, and tissue-
resident macrophages such as alveolar macrophages (lung), osteoclasts and bone marrow 
macrophages (bone), microglia (brain), Langerhans cells (dendritic cells in the skin), 
crypt macrophages (intestine), Kupffer cells (liver), uterine dendritic cells and uterine 
macrophages (208).  
Macrophages are bone marrow derived myeloid cells, and are continuously 
repopulated (84).  Repopulation commonly occurs by extravasation and differentiation of 
monocytes from systemic circulation; half of the blood monocytes leave systemic 
circulation daily (84).  Two populations of monocytes have been identified in circulation, 
one which responds to inflammation (M1 and M2 macrophages, dendritic cells), and one 
which repopulates noninflamed tissues (resident macrophages, some dendritic cells eg. 
Langerhans cells) (84).  Thus, the monocyte lineage and the tissue microenvironment 
dictate monocyte extravasation, differentiation, and macrophage phenotype.
1
Macrophages exposed to bacterial and parasitic components, collectively termed 
pathogen associated molecular patterns (PAMPs), and to cytokines such as interferonγ 
(IFNγ), were among the first macrophages to be investigated as part of the innate immune 
system, and are referred to as classically activated or M1 macrophages (123, 208).  A key 
component of the M1 macrophage phenotype is the production of nitric oxide (NO) by 
inducible nitric oxide synthase (iNOS) from molecular O2, L-arginine, and NADPH (148, 
155, 245).  The ability of M1 macrophages to produce NO is essential for the effective 
elimination of several types of infections (6, 94, 96, 215, 265).  However, dendritic cells 
(233), microglia cells (14, 210, 234), and some tumor associated macrophages (typically 
thought to be M2 macrophages) (102), have also been demonstrated to upregulate iNOS, 
suggesting NO production and its effects may not be limited to M1 macrophages.  In our 
studies of NO production, two stimuli known to induce macrophage iNOS were utilized: 
lipopolysaccharide (LPS) and IFNγ.
LPS is the primary component of the outer membrane of gram-negative bacteria 
(5).  LPS binding to CD14 and TLR4/MD2 on the macrophage cell surface results in 
signaling through multiple adaptor proteins including Src kinases, protein kinase C, PI3-
kinase, mitogen activated protein kinases, phospholipase D, Gi/Go proteins, protein 
kinase A, FKBP12-rapamycin-associated protein, MyD88, IRAK, and TRAF6 (5, 25). 
Signaling through these proteins activates the transcription factors, NFκB, C/EBP, AP-1 
(5, 25), and even HIF1 in normoxic differentiated macrophages (31, 195).  NFκB, NF-
IL6 (a C/EBP transcription factor), and HIF1 have been shown to bind to regions in the 
iNOS promoter and upregulate iNOS transcription (63, 95, 126, 163, 170, 181, 205, 288).
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IFNγ is produced by activated T lymphocytes and natural killer cells, and acts in a 
paracrine manner on macrophages (19, 60).  IFNγ binds to the IFNγ receptor, which 
signals through the adaptor proteins JAK2, MEK1/2, and Erk1/Erk2 to activate the 
transcription factor STAT1α (19, 29).  STAT1α binds to the iNOS promoter (80, 170, 
288), and to the IRF-1 promoter (146), at the gamma-interferon activated site.  STAT1α 
and IRF-1 binding to the iNOS promoter is necessary for IFNγ mediated upregulation of 
iNOS transcription (80, 139, 170, 174).
LPS and IFNγ treatment of macrophages results in the upregulation of iNOS 
mRNA by 3 hours, and protein by 6 hours, with maximal protein concentration and 
activity observed at 24 hours (4, 61).  NO production continues for up to 2 days (9), at 
which point the cells die via apoptosis (8, 224), most likely mediated by the continued 
exposure to nitrosative stress (103, 173).  iNOS cleavage and degradation by calpain 1 
(267, 268) and the ubiquitin-proteosome pathway (189) occurs with a half life of 1 ½ 
hours in atmospheric O2 (145), suggesting continuous production of the enzyme is 
necessary to enable this prolonged NO production.  For the experiments described herein, 
we chose to investigate the effects of acute hypoxia at 24 hours after LPS and IFNγ 
stimulation of RAW 264.7 cells, a macrophage-like transformed cell line, to ensure 
robust and reproducible NO production.
Coexistence of Macrophage NO Production and Hypoxia in vivo
Molecular O2 is a cosubstrate for NO production (148, 155), thus the partial 
pressure of oxygen (pO2) has the potential to affect macrophage function in vivo. 
Physiological tissue pO2 measurements are 5 to 71 Torr (23, 32, 37, 42, 87, 88, 124, 129, 
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159, 253, 254, 263, 266, 281, 282), indicating that even in the absence of hypoxia (pO2 < 
the normal pO2 for the tissue), macrophages are exposed to a wide range of pO2. 
Macrophages are exposed to hypoxia when tissue pO2 decreases due to cardiovascular 
compromise and/or overwhelming metabolic demand, such as in the wound environment 
(116, 194, 213, 236) and in multiple inflammatory diseases: sepsis (118, 122), cancer (37, 
38, 69, 70, 79, 111, 166), hypoxia-mediated pulmonary hypertension (154, 225), hypoxic 
brain injury (125, 196, 220), congenital heart defects (72), necrotizing enterocolitis (45), 
sleep apnea (75, 119, 295), asthma (17, 132, 289), cerebrovascular stroke (160), and 
atherosclerosis (28, 34, 43).  Three examples will be discussed: wound healing, sepsis, 
and cancer.
The pO2 measured in the center of the wound environment can be as low as 0 to 2 
Torr (225).  Wound healing is typically thought to occur in three stages: inflammation, 
proliferation, and maturation (285).  Consistent with this model, macrophages have been 
shown to to express iNOS for the first 24 to 72 hours of healing, and to become the 
predominant cell type within the wound on days 3 to 5 (211).  iNOS knockout mice have 
delayed wound healing, which can be improved with gene transfer of the human iNOS 
gene via an adenoviral vector (293), indicating that the presence of iNOS influences 
wound healing.  Nitrite and nitrate, metabolites of NO, are increased in the wound fluid 
isolated from a sponge model of wound healing during the first 24 to 48 hours (177). 
However, hypoxia (~ 0 Torr) has been shown to limit wound macrophage NO production 
in vitro, and to result in the redirection of L-arginine metabolism to arginase (7).  Further 
investigation of NO production by macrophages expressing iNOS in a hypoxic 
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environment is required to better understand how macrophages produces NO during 
wound healing.
Improper wound healing and bacterial invasion into systemic circulation can lead 
to the development of sepsis, a systemic inflammatory response (36).  The progression of 
sepsis to acute respiratory distress syndrome (ARDS) and multiorgan failure (MOF) is 
one of the most frustrating syndromes to treat in human and animal emergency rooms and 
intensive care units due to the rapidity of its progression (within 24 to 48 hours), and to 
the high mortality rate in this patient population (20 to 50% in humans, 60% in dogs) (24, 
64, 76, 175, 185, 228, 248).  Patients initially become locally hypoxic due to the 
redirection of blood flow to the vital organs and increased metabolic demand, and 
subsequently become systemically hypoxic due to circulatory and pulmonary collapse 
(118).  NO production by PAMPs stimulated macrophages has been implicated in this 
progression (44, 252).  
Excessive amounts of nitrosylated and nitrated proteins, markers of endogenous 
NO production (91, 262), have been detected in urine, plasma, and affected organs from 
septic patients (86, 89, 140, 197, 243).  iNOS has been demonstrated to directly bind, 
nitrosylate, and increase the activity of cycloxygenase-2, even in the presence of 
oxyhemoglobin, an extracellular NO scavenger (137).  Alternatively, some nitrated 
proteins have impaired function e.g. surfactant protein A can no longer aggregate lipids 
(101).  The NO metabolite, peroxynitrite, inhibits oxygen consumption by alveolar type 
II cells (113), and mediates pulmonary cell damage and death (90).  The ensuing hypoxia 
due to impaired pulmonary gas exchange is exacerbated by the concurrent circulatory 
dysfunction due to macrophage NO production.  iNOS has a Vmax that is 5 fold greater 
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than the Vmax for endothelial NOS (eNOS) and neuronal NOS (nNOS) (214).  Thus, one 
of the major mechanisms contributing to generalized vasodilatation and septic shock is 
the larger amount of NO produced by macrophages in similar tissue microenvironments 
as endothelial cells (118, 252).
Because of these negative effects of NO production, nonspecific NOS inhibitors 
(i.e. inhibition of iNOS, eNOS, and nNOS) were tested in animal models of sepsis (55, 
77, 133-135, 183, 198, 244, 256, 257), and in human Phase I (97, 117), II (21, 272), and 
III (167) clinical trials.  Although effective in preventing the decrease in blood pressure 
observed due to septic shock (21, 55, 97, 133-135, 167, 244, 272), in the Phase III 
clinical trial patient mortality was ultimately increased, and the trial was terminated prior 
to completion (167).  Specific inhibitors of iNOS have been shown to have some benefit 
in animal models (151, 161, 176, 199, 221, 249).  However, bacterial sepsis in iNOS 
knockouts results in increased mortality (54), or no survival advantage (152, 193), 
probably due to the role of macrophage NO production in innate and adaptive immunity 
(6, 94, 96, 215, 265).  Thus, even specific inhibition of iNOS needs to be carefully 
evaluated for its utility in treating septic patients.  Macrophage NO production may 
already be limited due to the tissue hypoxia, and more information is needed to enable the 
development of NO targeted therapeutic strategies for sepsis.
A third example of macrophage exposure to hypoxia is within tumors.  Hypoxia 
has been documented in 50 to 60% of all solid tumors (166), and has been shown to 
correlate with poor clinical outcome (37, 38, 69, 70, 79, 111, 166).  Chronic 
inflammation has been linked to the development of cancer (162), and while tumor 
associated macrophages (TAM) are predominantly thought to have an M2 phenotype, 
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they have been demonstrated to express iNOS (235).  Tumor cells themselves can also 
express iNOS (12, 104, 261), and increased serum nitrite and nitrate levels correlated 
with poor survival in lung cancer patients (56).  However, some studies have shown that 
NO can inhibit tumorigenesis and metastasis, and whether NO is beneficial or detrimental 
has been proposed to depend on the location, degree, and timing of NO production (283, 
284).  
Anti-tumorigenic properties of NO include inhibition of mitochondrial respiration 
(65, 246) and the induction of apoptosis (103, 173).  Pro-tumorigenic properties include 
genotoxic effects (71), increased iron uptake (66, 106, 255), promotion of angiogenesis 
(12, 261), and promotion of tumor growth and metastasis (50, 83, 207, 291).  The p53 
status of the tumor is one mechanism which appears to determine whether NO is pro- or 
anti-tumorigenic.  p53 positive tumor cells typically undergo apoptosis due to NO 
exposure, whereas p53 negative cells have increased VEGF production, resulting in the 
promotion of angiogenesis (283).  
In normoxic cells, NO increases VEGF production via HIF-1α stabilization, DNA 
binding, and transcriptional activity (138, 204, 222, 223).  However, in hypoxic cells, NO 
decreased HIF-1α stabilization and HIF-1 activity (3, 114, 165, 238, 269), suggesting the 
presence of hypoxia can affect the pro- versus anti-tumorigenic status of NO.  Hypoxia 
also stimulates VEGF production via HIF1 activation (15, 231, 274) and increases iron 
uptake (51, 255).  A better understanding of the hypoxic effects on macrophage NO 
production is needed to elucidate how hypoxia and NO interact and contribute to cancer 
development and progression.
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In summary, NO producing macrophages are exposed to a wide range of pO2, and 
the requirement of molecular O2 for NO production (148, 155) suggests that tissue pO2 
has the potential to influence macrophage NO generation.  The presence of macrophage 
NO production is a double edged sword for most diseases: some effects are beneficial 
while others are detrimental to the host.  The affect of macrophage NO production on 
patient outcome (quality of life, and life vs. death) often seems to depend on the location, 
timing, and degree of NO production, all of which will be affected by tissue pO2.  Thus, 
understanding the effects of pO2 on macrophage NO production is essential to 
understanding the pathogenesis of multiple diseases.
Hypoxic Affects on NO production and iNOS in vitro
The effect of hypoxia on iNOS activity has been investigated in numerous models 
(1, 2, 13, 46, 67, 110, 136, 179, 182, 202, 214, 296).  Consistent with the role of 
molecular O2 as a cosubstrate (148, 155), NO production uniformly was decreased during 
hypoxia.  However, the degree and duration of hypoxia required for this decrease, and the 
mechanisms mediating this effect, have not been clearly defined.
The apparent KmO2 for isolated iNOS has been reported to be 6.3 ± 0.9 µM (5 ± 
0.6 Torr) (214), 130 µM (93 Torr) (1), and 135 µM (96 Torr) (67).  There are three 
possible mechanisms explaining the differences between the studies: 1) the source of 
iNOS, 2) the method of measurement, and 3) the method of pO2 control.  When NO was 
scavenged with oxyhemoglobin, the apparent KmO2 was reduced approximately 4 fold 
from 130 µM (93 Torr) to 42 µM (30 Torr) (1).  Abu-Soud et al. propose that the removal 
of NO feedback inhibition by the scavenging of NO with oxyhemoglobin mediates the 
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shift they measured in the apparent KmO2 (1, 247).  However, details regarding the 
contribution of additonal O2 by oxyhemoglobin, a factor which could also cause a shift 
toward a lower apparent KmO2, are not available.
The apparent KmO2 in stimulated macrophages has been investigated in two 
studies.  In one study, nitrite was measured following treatment with LPS and IFNγ for 
24 hours at various pO2, and a calculated apparent KmO2 of 10.8 ± 2.0 % (77 ± 1.4 Torr) 
was reported (179).  Under similar culture conditions, Otto and Baumgardner measured a 
hypoxia mediated decrease in iNOS activity at the conclusion of the exposure period (18 
hours) via the citrulline assay in cell lysates at atmospheric O2, suggesting an effect of 
pO2 on the specific activity and/or the amount of active iNOS, in addition to reactant 
limitation (202).  After normalizing nitrite production for changes in iNOS activity, and 
accounting for the O2 diffusion gradient from the headspace gas to the cell surface, their 
estimate for the apparent KmO2 at the cell surface was 14 Torr (202).  Thus, the reported 
apparent KmO2 for iNOS spans a wide range (5 Torr to 96 Torr), making it difficult to 
assess which pO2 could regulate NO production in vivo.
The duration of hypoxia required for decreased macrophage NO production has 
not been previously investigated.  Prior studies relied on indirect measurement of NO 
after 18 to 24 hours of concurrent exposure to LPS, IFNγ, and hypoxia (179, 202). 
Therefore, the effects of hypoxia on iNOS upregulation could not be separated from the 
effects due to reactant limitation.  The amount of active iNOS, and the iNOS velocity, 
during the 24 hour period may vary tremendously because of hypoxic effects on iNOS 
mRNA, iNOS protein concentration, iNOS dimerization, and reactant availability.
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Hypoxic induction of iNOS is mediated by the transcription factor, HIF-1 (126, 
205).  HIF-1 is a dimer composed of HIF-1α and HIF-1β subunits.  Both subunits are 
constitutively expressed in most tissues (280).  However, the HIF-1α protein is rapidly 
degraded via the ubiquitin-proteosome pathway in the presence of O2 (59, 229, 230). 
Hypoxia increases HIF-1 DNA binding to the iNOS hypoxia responsive element (HRE), 
which upregulates iNOS transcription (126), (205).  Upregulation of iNOS in rat primary 
cardiac myocytes was measured at 12 hours (126).  In contrast, hypoxic exposure 
durations ≤ 24 hours did not increase iNOS mRNA in the CRL-2192 alveolar 
macrophage cell line or in rat lungs (4).  Exposure of rats to hypoxia (10% inspired pO2) 
for 3 weeks increased iNOS mRNA in the lung (147, 198).  These results suggest the 
temporal effects of hypoxia on iNOS mRNA depends on the cell type.  Co-stimulation of 
CRL-2192 alveolar macrophages with LPS or IFNγ and hypoxia, or treatment of rats with 
LPS immediately prior to hypoxia (9% inspired pO2), expedited the upregulation of iNOS 
mRNA in the macrophages and in the lung, respectively, with an observed effect as early 
as 3 hours (4).
Hypoxic upregulation of iNOS mRNA has not always resulted in increased iNOS 
protein concentration.  iNOS protein was decreased in LPS, IFNγ, and hypoxia stimulated 
RAW 264.7 cells (24 hours (202)), and in TNFα, IL1β, and hypoxia stimulated rat 
pulmonary artery cells (296).  In contrast, iNOS protein was increased in LPS or IFNγ 
and hypoxia stimulated CRL-2192 macrophages (4) and ANA-1 macrophages (182), and 
in the lungs of rats treated with LPS, and then with 3, 6, or 12 hours of hypoxia (9% O2) 
(4).  Rats maintained in hypoxia (10% O2) for 3 weeks were also shown to have increased 
iNOS protein in their lungs (154).  Thus, the degree and duration of hypoxia, cytokine 
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concentration, combination of cytokines, and/or cell type appear to determine whether 
upregulated iNOS mRNA correlates with increased iNOS protein concentration.
Following the upregulation of iNOS mRNA and protein expression, dimerization 
is necessary for NO production (20).  Dimerization requires BH4 (20, 147, 209, 260, 
275), heme (20, 239), and L-arginine (20).  Preliminary data in our laboratory measured a 
decrease in the iNOS dimer:monomer ratio in RAW 264.7 cells costimulated with LPS, 
IFNγ, and hypoxia (24 hours), which was fully reversible by L-sepiapterin, a 
pharmacologic source of BH4 (201).  Cytokine stimulation increases macrophage BH4 
concentration via increased activity of the rate limiting enzyme, GTP cyclohydrolase I 
(85, 276-278).  Thus, these preliminary results suggest hypoxia may limit BH4 
availability despite increased activity of GTP cyclohydrolase I.
Hypoxic Affects on NADPH and L-arginine availability
In addition to O2 substrate limitation, hypoxia has been reported to affect NADPH 
and L-arginine availability.  NADPH is produced by the oxidative pentose phosphate 
cycle (OPPC) in LPS and IFNγ stimulated macrophages (58).  An association between 
NADPH production by glucose 6 phosphate dehydrogenase (G6PD), the rate limiting 
enzyme of the OPPC, and NO production has previously been demonstrated in 
macrophages (57, 112, 180, 258), and pharmacologic inhibition of OPPC activity or 
G6PD deficiency was shown to significantly impair NO production (112, 180, 258). 
Classical studies have measured increased [NADPH] in response to short term hypoxia 
due to the absence of oxidizing agents (99, 127, 227, 259).  More recently, however, 
decreased [NADPH] was measured in denuded bovine coronary arteries following brief 
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exposure to hypoxia (~ 8 to 10 Torr, 20 minutes (100)).  The effect of hypoxia on 
macrophage OPPC activity and [NADPH] has not been investigated.
The concentration of L-arginine in cell culture media (JBMEM: 300 µM, MEM: 
700 µM) is well above the apparent Km for arginine (2.8 µM; (245)), and is not expected 
to be limiting for these studies.  In addition, LPS and hypoxia increase the mRNA of the 
arginine transporter, MCAT-2B (169), suggesting cellular L-arginine import is increased. 
However, hypoxia (24 hours) alone and in combination with LPS has also been shown to 
upregulate macrophage arginase (7, 169), which has been proposed to compete with 
iNOS for L-arginine as a substrate (48, 108, 250).  Inhibition of arginase can increase NO 
production by stimulated macrophages, and vice versa (109).  However, the interplay 
between iNOS and arginase is cell specific (226), cytokine specific (107, 270), and time 
dependent (270).
Specific Aims
In summary, hypoxia has the potential to alter macrophage NO production by 
multiple mechanisms.  Due to the difficulties of culturing cells at defined pO2, and the 
difficulties of measuring NO production directly, previous studies were not able to 
evaluate the effects of an abrupt change in pO2 on NO production.  Therefore, the first 
aim of this work was to measure macrophage NO production directly, and in real time, 
during precise and accurate step changes in pO2 using a novel forced convection cell 
culture system (Chapter 1).  A decrease in NO production could be mediated by 
limitation of the reactant(s) or an effect on iNOS itself.  Limitation of molecular O2 is the 
most intuitive mechanism.  However, hypoxic exposure has also been documented to 
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affect the amount of active iNOS, and the availability of NADPH and L-arginine. 
Therefore, the second specific aim of this work was to investigate the contribution of 
these alternate mechanisms to the regulation of NO production during acute hypoxia 
(Chapters 1, 2, and 3).
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CHAPTER 1.
PHYSIOLOGICAL AND HYPOXIC O2 TENSIONS RAPIDLY REGULATE NO 
PRODUCTION BY STIMULATED MACROPHAGES
Mary A. Robinson1,2,3, James E. Baumgardner4,5, Virginia P. Good2, and Cynthia M. Otto1,2,
1Department of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of 
Pennsylvania Philadelphia PA 19104; 2Center for Sleep and Respiratory Neurobiology, 
University of Pennsylvania Philadelphia PA 19104; 3Department of Radiation Biology, School of 
Medicine, University of Pennsylvania Philadelphia PA 19104; 4Department of Anesthesiology 
and Critical Care, School of Medicine, University of Pennsylvania Philadelphia PA 19104; 
5Oscillogy, LLC Folsom PA 19033. 
Published on February 13th, 2008 in the American Journal of Physiology Cell Physiology
Volume 294, Pages 1079 – 1087
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ABSTRACT
NO production by inducible nitric oxide synthase (iNOS) is dependent on O2 
availability.  The duration and degree of hypoxia which limit NO production are poorly 
defined in cultured cells.  To investigate short term O2-mediated regulation of NO 
production, we used a novel forced convection cell culture system to rapidly (response 
time = 1.6 seconds) and accurately (± 1 Torr) deliver specific O2 tensions (from < 1 to 
157 Torr) directly to a monolayer of LPS and IFNγ stimulated RAW 264.7 cells while 
simultaneously measuring NO production via an electrochemical probe.  Decreased O2 
availability rapidly (≤ 30 seconds) and reversibly decreased NO production with an 
apparent KmO2 of 22 (SD 6) Torr (31 µM) and a Vmax of 4.9 (SD 0.4) nmol/min·106 cells. 
To explore potential mechanisms of decreased NO production during hypoxia, we 
investigated O2-dependent changes in iNOS protein concentration, iNOS dimerization, 
and cellular NO consumption.  iNOS protein concentration was not affected (p = 0.895). 
iNOS dimerization appeared to be biphasic (6 Torr (p ≤ 0.008) and 157 Torr (p ≤ 0.258) 
> 36 Torr), but did not predict NO production.  NO consumption was minimal at high O2 
and NO tensions and negligible at low O2 and NO tensions.  These results are consistent 
with O2 substrate limitation as a regulatory mechanism during brief hypoxic exposure. 
The rapid and reversible effects of physiological and pathophysiological O2 tensions 
suggest that O2 tension has the potential to regulate NO production in vivo.
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INTRODUCTION
Macrophage NO production via inducible nitric oxide synthase (iNOS) is a key 
component of the cellular inflammatory response (33, 172).  In vivo, in vitro, and isolated 
enzyme experiments have clearly demonstrated the dependence of NO production on O2 
tension for all 3 of the NOS isoforms (1, 2, 13, 46, 67, 110, 136, 179, 182, 202, 214, 
296).  Normal non-pulmonary tissue O2 tensions range from 5 to 71 Torr (23, 37, 42, 124, 
129, 263, 282), and systemic and/or tissue hypoxia develops during several inflammatory 
diseases (42, 75, 122), extending the range for tissue macrophages to even lower levels. 
Alveolar macrophages can be exposed to O2 tensions ranging from approximately 30 
Torr (mixed venous O2 tension with atelectasis) to over 650 Torr (with O2 therapy) (279). 
Thus, macrophages must function over a wide range of physiologic and 
pathophysiological O2 tensions, and O2 tension has the potential to regulate macrophage 
NO production (67, 179, 202, 214).  It is currently unknown, however, if the macrophage 
response to changing O2 tension is rapid enough for O2 to play a role in the regulation of 
NO production.
Prior studies have explored the long-term effects (18 and 24 hours) of culture PO2 
(partial pressure of O2) on nitrite production in LPS and IFNγ stimulated RAW 264.7 
cells, but estimates of the apparent KmO2 have varied considerably.  McCormick et al. 
reported an apparent KmO2 of 10.8% (77 Torr) for the PO2 in the headspace gas (179).  In 
contrast, Otto and Baumgardner estimated the apparent KmO2 at the cell surface to be 14 
Torr, after normalizing to iNOS activity and accounting for the O2 diffusion gradient 
through the media layer (202).  This wide range of reported KmO2 may be in part due to 
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difficulties in accurately controlling headspace (202, 242) and cellular (22, 202) PO2 in 
conventional cell culture. 
No prior studies of macrophage NO production explored the effects of short-term 
exposure to different O2 tensions, primarily due to the limitations of conventional cell 
culture and NO analysis methods.  First, diffusion of O2 through the media covering cells 
cultured in dishes can be slow, requiring as long as 30 minutes for a change in headspace 
PO2 to be translated to the cell surface (10, 22).  Second, the sensitivity of nitrite 
measurement via the Griess method, which integrates NO production over the period of 
the experiment, is not adequate for short time periods with less NO accumulation (121, 
179, 202).
Forced convection cell culture utilizes a continuous flow of media to deliver O2 
and nutrients directly to the cell monolayer, and to remove waste products (22).  Because 
this method of cell culture overcomes the limitations of extracellular O2 diffusion, it is 
ideally suited for measuring the effects of rapid changes in O2 tension.  In addition, the 
system used for the present study controls O2 tensions with an accuracy of about 1 Torr, 
and permits rapid, direct measurement of changes in NO in the effluent using a sensitive 
electrochemical probe (216, 217). Thus, the first goal of our current study was to use this 
recently developed method to accurately define the PO2 dependence of NO production by 
LPS and IFNγ stimulated RAW 264.7 cells, after brief exposures to a range of 
physiological and hypoxic O2 tensions.
The second goal of our study was to evaluate three mechanisms that could alter 
NO production after brief hypoxic exposures.  The oxygen atom in NO is derived from 
molecular O2 (148, 155).  Prior cell culture studies which used long term exposures to 
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varying O2 tensions, and studies with isolated nitric oxide synthases (NOS), have 
emphasized the potential role of O2 as a rate-limiting substrate (67, 179, 202, 214).  O2 
has also been shown to participate in more complex interactions with the NOS enzyme 
than simple substrate dependence (247).  These mechanisms could operate on a short 
enough time scale to alter NO production after brief hypoxic exposures.  There are, 
however, several additional opportunities for changes in PO2 to rapidly influence NO 
production.  Our goal was to evaluate three of these additional mechanisms: changes in 
the cellular levels of inducible NOS (iNOS) protein, changes in iNOS dimerization, and 
changes in cellular NO consumption.  We hypothesized that: 1) brief hypoxic exposures 
would reduce NO production by reducing iNOS protein; 2) brief hypoxic exposures 
would reduce NO production by reducing iNOS dimerization; and 3) brief hypoxic 
exposures would reduce NO production and release from the cell by increasing 
intracellular consumption of NO.
MATERIALS AND METHODS
Forced Convection Cell Culture.
RAW 264.7 cells (American Type Culture Collection, Manassas, VA) were 
cultured using a novel forced convection cell culture system as described previously (22). 
Briefly, cells were aspirated through a ProNectin® F-coated (0.1mg/ml; Sigma, St Louis, 
MO) 0.53 mm diameter, 10 cm long fused-silica capillary column (Alltech, Deerfield, 
IL), allowed to adhere for 15 minutes, and cultured with forced convection in air with 5% 
CO2 for 18 to 22 hours in the presence of 1 µg/ml LPS (E. coli O111:B4; Sigma) and 100 
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U/ml CHO-derived recombinant mouse IFNγ (Cell Sciences, Canton, MA) in DMEM 
(Gibco, Carlsbad, CA) supplemented with 5% heat-inactivated FBS (LONZA, Visp, 
Valais, Switzerland) and 1% antibiotic/antimycotic (penicillin, streptamycin, fungizone; 
Life Technologies, Gaithersburg, MD).  Following stimulation, the column of cells was 
transferred to the forced convection cell culture system (Figure 1).
Experiments were performed in a minimal essential media (JBMEM: 140 mM 
NaCl, 1.4 mM CaCl2, 5.3 mM KCl, 4.4 mM Dextrose, 25 mM HEPES, 0.3 mM L-
arginine, and 0.1% heat-inactivated FBS (LONZA)) equilibrated with 0, 0.7, 3.6, 8.4, 
15.2, 25.8, 38.0, 85.3, or 159.6 Torr O2 (5% CO2, balance N2) from certified premixed 
compressed gas cylinders (AirGas, Allentown, PA).  Corresponding estimates of average 
cellular PO2, after accounting for cellular O2 consumption, were 0, < 1, 1, 6, 13, 24, 36, 
83, or 157 Torr O2 (22).  Upon completion of experiments, the fluid was briefly switched 
to PBS equilibrated with the experimental O2 tension, and then the column of cells was 
removed from the system and immediately frozen at -70°C.
Measurement of Effluent NO Tension.
NO was detected using a 2 mm NO electrode (NOP, World Precision Instruments, 
Sarasota, FL) filled with a CO2 insensitive electrolyte (World Precision Instruments).  To 
enable calibration of the NO electrode, the forced convection cell culture system was 
adapted to allow defined amounts of NO (input NO) to be added to the fluid stream 
(Figure 1).  Deionized H2O (dH2O) was deoxygenated via a membrane equilibrator with 
certified ultra high purity N2 (AirGas), then equilibrated via a second membrane 
equilibrator with 2000 ppm NO in N2 (AirGas).  As in our prior report (6), function of all 
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membrane equilibrators was tested by confirming flow independence of the measured gas 
partial pressure in the equilibrator effluent.  Defined amounts of 2000 ppm NO-
containing dH2O were injected into the fluid stream using a syringe pump (Harvard 
Apparatus, Holliston, MA).  The electrode was calibrated with input PNO of 19, 40, 79, 
160, 319, and 500 ppm at the beginning of each day.  In the forced convection system, 
the measured 0-95% time constant for the probe was 27 seconds.  Due to NO probe 
baseline drift during experiments, the NO probe baseline was measured regularly (i.e. ≤ 5 
minute intervals) to allow for manual baseline correction of the data.
All NO measurements were performed in JBMEM, which was designed to 
minimize media NO consumption while maintaining cell viability.  To evaluate NO 
consumption by JBMEM, the forced convection system depicted in Figure 1 was 
modified by inserting two lengths of fused silica (13 cm and 30 cm) between the NO 
input site (labeled T in Figure 1) and the outlet valve (labeled B in Figure 1), resulting in 
exposure of NO to the media for 9 and 18 seconds, respectively.  The NO signal was 
recorded for each exposure duration at two input PNO (160 and 320 ppm), and at three PO2 
(0, 40 and 80 Torr).  PO2 dependence of NO consumption in JBMEM was further 
investigated after restoring the system to the configuration of Figure 1 (i.e. 16 cm of 
tubing between the NO input and the inlet valve, labeled A in Figure 1, and 10 cm of 
tubing between the inlet valve and the outlet valve) in the absence of cells at five PNO (40, 
79, 160, 319, 500 ppm) and six PO2 (0, 15, 26, 38, 85, 160 Torr).  To test if JBMEM was 
sufficient to support cell viability, RAW 264.7 cells were seeded onto 6 well plates (9.5 
cm2) and cultured in a humidified incubator (room air, 37°C, 5% CO2) in either DMEM 
or JBMEM.  Viability was measured by Trypan blue staining after 2, 6 or 18 hours of 
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culture.  Cells were evaluated with and without stimulation (1 µg/ml LPS and 100 U/ml 
IFNγ initiated 18 hours prior to seeding).
Electrophoresis and Immunoblotting.  
Cell lysates were prepared from columns by aspirating ice cold protease-inhibitor 
containing hypotonic lysis buffer (PIB: 10 µM phenylmethylsulfonyl fluoride (ICN 
Biochemical, Aurora, OH), 5 µg/ml aprotinin (Sigma), and 5 µg/ml pepstatin (Amresco, 
Solon, OH) in dH2O) through each column.  Cell lysate protein concentrations were 
measured using the Biorad DC protein assay (Hercules, CA).
Proteins (10 µg) were separated on a 7.5% Tris-HCl gel using SDS PAGE or low 
temperature SDS PAGE (LT SDS PAGE) as previously described (287), except the final 
β-mercaptoethanol concentration for samples subjected to LT SDS PAGE was 0.1% 
(v/v).  Proteins were transferred to polyvinylidene fluoride (ImmobilonTM-FL 0.2µm; 
Millipore, Bedford, MA) and immunoblotted for iNOS (1:1000 to 1:2000; NOS2 M19 
sc650, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and the loading control, Raf-1 
(1:200 to 1:500; Raf-1 sc227, Santa Cruz Biotechnology, Inc.).  Primary antibodies were 
immunocomplexed with IRDyeTM 800 goat anti-rabbit (1:20,000; Rockland, Gilbertsville, 
PA).  Proteins were detected, documented, and analyzed using an Odyssey Imaging 
System and software (LiCor Biosciences, Lincoln, NE).
Cellular NO Consumption.
Endogenous NO production by LPS and IFNγ stimulated RAW 264.7 cells 
cultured in the forced convection system was inhibited by a 36 to 48 minute exposure to 
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100 µM N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide, dihydrochloride (1400W; 
Cayman Chemical, Ann Arbor, MI) in JBMEM lacking L-arginine.  Maximal NO 
inhibition by 1400W (86 SD 7 % of basal NO production; n = 8), was expedited by 3 to 4 
periods of stopped flow for 5 minutes followed by 7 minutes of flow.  Once maximal 
inhibition of endogenous NO production was achieved, cells were returned to JBMEM 
with L-arginine and were sequentially exposed to input PNO of 40, 79, 160, 319, 500, and 
0 ppm in the presence of 6, 36, or 83 Torr O2.  Average effluent PNO was recorded for 
each input PNO once steady state was achieved, and was compared to average effluent PNO 
recorded on the same day for the same input PNO in the absence of cells.  The difference 
between effluent PNO with cells and without cells for each input PNO was assumed to be 
due to the net result of NO consumption and residual endogenous NO production. 
Testing for zero order, first order, or higher order dependence of NO consumption on PNO 
and PO2 was performed, and the data were analyzed, by considering a mass balance on 
the cell column:
(NO entering the column) – (NO leaving the column) = consumption – production 
Production represents the small amount of residual cellular NO production that was not 
inhibited by 1400W treatment.  Consumption represents overall cellular degradation of 
NO from all irreversible and slowly reversible reactions, for example reaction with 
superoxide to form peroxynitrite (30, 115), conversion to nitrate via the iNOS futile 
pathway (247), nitrosylation, nitration and oxidation of proteins (92), autoxidation (74, 
164), and other reactions (74, 212).
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Our analysis assumes that NO production is independent of NO concentration, 
since the range of NO concentrations we studied is below the range associated with NO 
feedback inhibition of inducible nitric oxide synthase (iNOS) (1).  Consumption is 
modeled, as a starting point, as first order in both NO and O2 (251).  It is known that 
autoxidation is second order in NO and first order in O2 (74), but the reaction is too slow 
to consume NO before it reaches the electrode.  Additionally, our data were calibrated to 
the effluent PNO detected for the five input PNO in JBMEM in the absence of cells and O2. 
Therefore, the detected NO consumption in our experiments is expected to be dominated 
by intracellular consumption reactions.  The mass balance on the column of cells 
becomes
QαNO(PNOi-PNOe) = kcN (PO2)(PNO) – f(PO2)kpN
Where: Q is the media flow rate through the column (4.27x10-6 L/sec)
αNO is the NO solubility in media at 37°C (2.13x106 pM/Torr) (271)
PNOi is the NO partial pressure in media entering the column (Torr)
PNOe is the NO partial pressure in media leaving the column (Torr)
kc is the consumption rate constant (pmol NO/ cell·sec·Torr2)
PO2 is the average oxygen partial pressure for cells in the column
PNO is the average NO partial pressure for cells in the column
f(PO2) is the functional dependence of NO production on PO2
kp is the maximal NO production for each column at high PO2 (pmol NO/ 
cell·sec)
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N is the number of cells in the column
Statistics.
Comparison of means were tested by a one way ANOVA for each PNO for PO2 
dependent NO consumption in the absence of cells (Figure 2), a two way ANOVA for the 
effects of DMEM versus JBMEM over time on cell survival (Table 2), and a three way 
ANOVA for the effects of input PNO, PO2 and exposure time on NO degradation in 
JBMEM using SigmaStat version 3.1.  All other statistics were performed using 
GraphPad InStat version 3.06 for Windows 95, GraphPad Software, San Diego, CA, 
www.graphpad.com.  Changes in NO production with repeated cycling between 0 and 36 
Torr O2 (Figure 3A) were tested by linear regression.  The apparent Km and Vmax were 
calculated by SigmaPlot Enzyme Kinetics Module 1.1 using a Michaelis-Menten non-
linear analysis (Figure 3C).  Comparison of means for iNOS protein concentration data 
(Figure 4) were tested by one-way ANOVA.  Comparison of means for iNOS 
dimerization data (Figure 5) were tested by pair-wise t-tests with a Bonferroni correction. 
Testing of the NO consumption model was performed with linear regression as described 
in Appendix A.
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RESULTS
Characteristics of JBMEM.
In the absence of O2 and cells, NO was rapidly consumed in DMEM by many of 
its components (Table 1), consistent with previous reports(39, 47, 131).  Consumption of 
160 and 320 ppm NO in JBMEM was investigated in the absence of cells at 0, 40, and 80 
Torr O2 by varying exposure duration.  Exposure duration (9 versus 18 seconds) and PO2 
had no effect on the measured NO signal (n ≥ 2; p = 0.516 and p = 0.201, respectively), 
indicating negligible consumption by the media for exposures less than 18 seconds. 
Consistent with these observations, PO2 dependent NO consumption in JBMEM was not 
detectable for any of the input PNO investigated with the system in its standard 
configuration as depicted in Figure 1, with a 15 second transit time from the NO input to 
the NO electrode (Figure 2; n = 3; 500 ppm, p = 0.152; 319 ppm, p = 0.264; 160 ppm, p = 
0.370; 79 ppm, p = 0.951; 40 ppm, p = 0.468).  For all subsequent experiments, NO 
consumption during the approximately 3.5 second average transit time from the cells to 
the NO electrode was therefore considered negligible.
In unstimulated cells, there was a small but significant reduction of cell viability 
with JBMEM (Table 2; p = 0.028).  There was no detectable effect of time (p = 0.074) or 
interaction between media type and time (p = 0.601).  In cells cultured with LPS and 
IFNγ, no significant effect of media (p = 0.364) or time (p = 0.894) was detected.
Effect of O2 tension on effluent PNO.
Steady-state NO release by LPS and IFNγ stimulated RAW 264.7 cells exposed to 
36 Torr O2 was 3.08 (SD 1.14) nmol/min·106 cells (n = 5).  Unstimulated cells did not 
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produce detectable NO (data not shown).  Exposure of the cells to 0 Torr O2 decreased 
effluent PNO within 30 seconds to an undetectable amount (Figure 3A).  Similarly, within 
30 seconds of re-exposure to 36 Torr O2, effluent PNO was greater than or equal to the 
initial measured concentration.  Repeated cycling between 0 Torr (2 minutes) and 36 Torr 
O2 (3 minutes) consistently produced these rapid changes in effluent PNO with a 
cumulative 10% increase in effluent PNO over a period of 40 minutes (p < 0.0001, n = 2). 
Unstimulated cells subjected to identical cycling patterns between 0 Torr and 36 Torr O2 
for 40 minutes did not produce detectable NO (data not shown).
Exposure of LPS and IFNγ stimulated RAW 264.7 cells to a range of O2 tensions 
elicited corresponding changes in effluent PNO, which predominantly followed a 
Michaelis-Menten kinetic model (Figure 3B).  A non-linear analysis computed an 
apparent KmO2 of 22 (SD 6) Torr and Vmax of 4.9 (SD 0.4) nmol/min·106 cells (n = 5, R2 = 
0.80).  A slight deviation from a smooth monotonic function is apparent between 6 and 
36 Torr O2 (Figure 3C).
Effect of O2 tension on iNOS.
O2 tension did not influence iNOS protein concentration (Figure 4, n ≥ 4, p = 
0.895), but did influence the bands thought to contain iNOS dimers (Figure 5, n = 3).  In 
the western blot derived from the partially denaturing gel, three bands were present: a 
band corresponding to the expected monomer molecular weight (~130 kD) (49), a band 
corresponding to the expected dimer molecular weight (~260 kD), and an unexpected 
band of much higher molecular weight (≥ 500 kD).  Compared to 36 Torr, the ratio of the 
260 kD band to the 130 kD band was significantly increased in lysates from samples at 6 
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Torr (p = 0.003).  A similar finding was observed for the ratio of the 500 kD band to the 
130 kD band (p = 0.008).  The ratios also appeared to increase in lysates from samples at 
157 Torr, but the increase did not achieve statistical significance (260 kD ratio p = 0.258, 
500 kD ratio p = 0.129).
Effect of NO and O2 tension on cellular NO consumption.
Following 1400W inhibition of endogenous NO production (Figure 6A), LPS and 
IFNγ stimulated RAW 264.7 cells at 6, 36, or 83 Torr O2 were exposed to five input PNO 
(Figure 6B).  Data are presented in Figure 6C as the ratio of effluent PNO with cells to 
effluent PNO without cells.  Net cellular NO consumption, as indicated by a ratio less than 
1, was evident at input PNO of 160, 319, and 500 ppm in PO2 of 36 and 83 Torr. 
Calculations based on known autoxidation rate constants (74, 164) estimated that 
autoxidation within the cells could account for a maximum of 3% of the measured NO 
consumption.  Cellular consumption was negligible at a PO2 of 6 Torr, regardless of the 
input PNO.  Net cellular NO production resulted in a ratio greater than 1 for the lower two 
input PNO (40 and 79 ppm) delivered in the lower two PO2 (36 and 83 Torr).  The amount 
of NO production was consistent with the residual cellular NO that was not inhibited by 
1400W.  Immediately following 1400W treatment, mean cellular NO production was 
14% (SD 7) (n = 8) of initial NO production.  By the end of the experiment, cellular 
production increased to 24% (SD 6) (n = 7) of initial NO production.  The relationship 
between net cellular NO consumption and PNO was most consistent with 1st order kinetics. 
NO consumption also correlated positively with PO2 in a 1st order-dependent manner at 
all PNO.  The overall consumption constant (kc) for the model was 0.038 pmol NO/sec·106 
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cells·Torr2 [12.7 (mmol NO)/(sec·106 cells·M2)].  Details of the consumption model are 
presented in Appendix A.
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DISCUSSION
Our study examined the effects of brief exposures to O2 tensions, ranging from < 
1 Torr to 157 Torr, on the production and release of NO by stimulated macrophages. 
Decreased PO2 rapidly and reversibly decreased NO production, with an apparent KmO2 
of 22 (SD 6) Torr.  Short term hypoxic exposures did not affect iNOS protein levels, but 
did influence iNOS dimerization.  Surprisingly, however, iNOS dimerization did not 
predict NO production.  NO consumption was small at high cellular O2 and NO tensions 
and was negligible at low O2 and NO tensions.
Our measured apparent KmO2 is within the range of values reported previously for 
long term exposures in macrophage cell culture (179, 202), and for the isolated iNOS 
enzyme (1, 67, 214).  It is also well within the range of PO2 that would be required for O2 
tension to regulate NO production in vivo, as has been suggested previously (1, 67, 179, 
202, 214).  Our study additionally demonstrated, however, that precisely controlled 
changes in extracellular O2 tension altered NO production by intact isolated cells within 
seconds, and that this effect was immediately reversible.  A slow response, or an 
irreversible response, would have argued against any role for the regulation of NO 
production by PO2 changes in intact cells. Instead, the effect on cellular NO production 
was rapid and reversible, further supporting a significant regulatory role for O2 tension in  
vivo.
Several studies have investigated PO2 dependence of NO production in intact 
tissues, and in vivo.  NO production has been shown to be rapidly decreased by hypoxia 
when the primary enzyme responsible for NO production was thought to be endothelial 
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NOS (eNOS) (110, 136), iNOS (67), or neuronal NOS (nNOS) (292).  O2-mediated 
intracellular kinetics and regulatory mechanisms, however, are difficult to evaluate in  
vivo and in tissue models due to the complications of tissue structure and O2 delivery 
dynamics.  Tissues are by definition composed of several different cell types with the 
potential for expression of several different NOS isoforms, and it is often difficult to 
unequivocally define which isoform is primarily responsible for producing the measured 
NO.  For example, in bronchial airways each isoform is expressed in different cells (35, 
67), and in different regions of the same cells (35, 290).  This could have important 
effects on total NO production, as the KmO2 for each isoform varies markedly in isolated 
enzyme studies (1, 214).  Although tissue and in vivo studies are not directly comparable 
to our cell culture study, they do support the concept that NO production can be rapidly 
regulated by changes in O2 tension in vivo.
We are not aware of any prior cell culture studies of NO production during brief 
exposure to hypoxia for the direct comparison to our results.  Two prior studies, however, 
investigated the effects of long term exposure ( ≥ 18 hours) to multiple O2 tensions on 
nitrite production by RAW 264.7 cells concurrently stimulated with LPS and IFNγ (179, 
202).  McCormick et al. measured cellular nitrite production following 24 hours of 
exposure to various headspace O2 tensions ranging from 1% to 21% (7 to 150 Torr).  The 
decrease in nitrite production at low O2 tensions was well described by a hyperbolic 
curve fit, and the apparent KmO2 for the headspace gas was 10.8% (77 Torr) (179).  Otto 
and Baumgardner measured cellular nitrite production following 18 hours of exposure to 
various headspace O2 tensions ranging from 1 to 677 Torr.  Nitrite production decreased 
with decreasing O2 tension throughout the entire range.  iNOS activity in cell lysates, 
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defined by citrulline production in room air at 25°C, also showed substantial dependence 
on cellular PO2 prior to lysis, suggesting an effect of O2 tension on specific activity 
and/or the amount of active iNOS.  After normalizing nitrite production for changes in 
iNOS activity, and accounting for the O2 diffusion gradient from the headspace gas to the 
cell surface, their estimate for the apparent KmO2 at the cell surface was 14 Torr (202). 
Studies of long term exposures to different O2 tensions are not strictly comparable to the 
short term exposures of the current study due to the many factors that could change 
slowly over time.  For example, O2 dependent changes in the transcription and translation 
of iNOS (4, 126, 179, 181, 182, 202), as well as of other relevant proteins (e.g. mediators 
of arginine metabolism (169)), would be expected to take several hours (4) and could 
substantially influence NO production in long term exposures, yet have minimal impact 
in short term exposures.
Three prior studies have investigated the apparent KmO2 for isolated iNOS.  Using 
a steady state kinetics approach, Rengasamy and Johns measured citrulline production at 
various PO2 by iNOS within a RAW 264.7 cell lysate.  In their system, O2 tension was 
rigidly controlled in the headspace gas by use of continuous gas flows, and the reaction 
mixture was constantly stirred to minimize diffusion gradients.  They reported an 
apparent KmO2 for iNOS of 6.3 µM, for a solution temperature of 37°C (214).  Using a 
rapid equilibrium kinetics approach, Abu-Soud et al. and Dweik et al. studied the effects 
of O2 tension on purified recombinant mouse iNOS by measuring the rate of NADPH 
oxidation spectroscopically, in a closed system at 25°C (1, 67).  They reported an 
apparent KmO2 of 130 µM (1) and 135µM (67).  When the NO produced was scavenged 
with oxyhemoglobin, however, the measured KmO2 was reduced approximately 4 fold to 
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42 µM (1).  The difference between these values was shown to be due to direct feedback 
inhibition of iNOS by NO, an effect that has been demonstrated for all 3 NOS isoforms 
(247).
In our experiments using forced convection cell culture, the flowing media 
continuously removed NO as it was produced, thereby minimizing NO accumulation. 
Our results, therefore, are most comparable to the isolated enzyme experiments that either 
continuously removed NO with flowing headspace gas in an open system (Rengasamy 
and Johns, KmO2 6.3 µM (214)), or scavenged NO with oxyhemoglobin in a closed 
system(Abu Soud et al., KmO2 42 µM (1)).  The apparent KmO2 we measured for intact 
cells was 22 (SD 6) Torr (31 µM based on an Ostwald solubility coefficient of 0.0271 ml 
O2 BTP/ml water-atm at 37°C (273)).  Unlike the isolated enzyme, within intact cells 
several mechanisms in addition to substrate dependence and product feedback inhibition 
could acutely alter NO production after a change in PO2.  We investigated 3 potential 
mechanisms: changes in iNOS protein levels, iNOS dimerization, and cellular NO 
consumption.
iNOS protein levels were not influenced by brief hypoxic exposures.  Hypoxia 
has been shown to induce increased expression of iNOS mRNA and protein via HIF 1α-
dependent regulation (126, 181, 182).  Acute changes in PO2, however, would not be 
expected to acutely increase iNOS protein production because transcription and 
translation have been shown to take up to 6 hours to change after an appropriate stimulus 
(4).  To our knowledge, the effect of hypoxia on iNOS degradation has not been 
investigated.  The iNOS half life in room air, however, was approximately 1.6 hours in 
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several cell types (145).  Our results showing that brief hypoxic exposures have little 
impact on iNOS protein are consistent with these previous studies.
iNOS dimerization was influenced by brief exposure to various O2 tensions, but 
surprisingly did not correlate with changes in NO production.  The changes in 
dimerization appeared to be biphasic (6 Torr and 157 Torr > 36 Torr), and were 
consistent for the 260 kD band, the expected size for iNOS dimers (49), and for the 500 
kD band, an undefined iNOS-containing protein complex.  Our data for NO production as 
a function of cellular O2 tension (Figure 3C), and data from a prior study on iNOS 
activity as a function of O2 tension (202), show deviations from a smooth monotonic 
function in that range of PO2, that may in part be related to the biphasic changes we 
observed in dimerization.  Decreased NO production despite a large increase in iNOS 
dimerization during hypoxia could be due to O2 substrate limitation, limitation of another 
substrate or cofactor during hypoxia, and/or the generation of inactive dimers.
Cellular NO consumption was negligible at all but the highest PO2 and PNO, with 
an overall consumption constant of 0.038 pmol NO/sec·106 cells·Torr2 [12.7 (mmol NO)/
(sec·106 cells·M NO·M O2)].  There are many possible intracellular reactants that can 
directly consume NO, and correspondingly, there are many possible reaction kinetics for 
cellular NO consumption (93, 150, 212).  Our data is most consistent with first order 
dependence in NO and O2, most similar to the findings of Thomas et al. (251).  Our 
consumption rates are at the low end of the reported range for various cell types (0.050 to 
1.61 pmol NO/sec·106 cells·Torr2) (81, 251), but are consistent with a previous report of 
LPS and IFNγ stimulated RAW 264.7 cells (0.011 pmol NO/sec·106 cells·Torr2 (190); 
see Appendix B for conversion of consumption constants to comparable units).
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In summary, we used a novel forced convection cell culture system to precisely 
regulate cellular O2 tensions in the range of < 1 Torr to 157 Torr.  In an LPS and IFNγ 
stimulated macrophage cell line, decreases in cellular PO2 reduced NO production within 
seconds, an effect which was immediately reversible with restoration of the original PO2. 
The apparent KmO2 for this oxygen dependence was 22 (SD 6) Torr (31 µM).  The 
changes in NO production were not explained by the effects of cell PO2 on iNOS protein 
levels, iNOS dimerization, or consumption of NO.  The rapid effects of cellular PO2 on 
macrophage NO production are consistent with regulation of NO production by O2 
substrate limitation.  The apparent KmO2 in intact cells and the kinetics of the PO2 
dependence suggest that O2 substrate limitation could play a dynamic role in the 
regulation of NO production by iNOS in vivo.
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APPENDIX A: NO Consumption Model
For each individual column, studied at a fixed PO2, QαNO(PNOi-PNOe) was plotted 
against PNO (Figure S1) to assess for linear dependence that would indicate that first order 
kinetics in NO are appropriate.  The negative intercept on this plot is production, i.e. 
intercept = -f(PO2)kpN, which could be of any functional form (for example the 
Michaelis-Menten fit in Figure 3).  The only assumption required about production for 
this analysis of NO consumption is that the production is independent of PNO.  
For the experiments at higher PO2 (36 and 83 Torr) in figure S1, a linear fit is 
clearly adequate, and the slopes were significantly different from zero.  At lower PO2, as 
the slope of this relationship approaches zero, the power to detect a slope significantly 
different from zero is reduced.  As expected, the trend for a linear relationship did not 
result in a slope significantly different from zero (p ≥ 0.122) for the PO2 = 6 Torr data 
sets.
For each column, the best fit slope (b1) of the QαNO(PNOi-PNOe) versus PNO data was 
divided by PO2 and plotted against PO2 (Figure S2).  First order dependence in PO2 
predicts that b1/PO2 should be independent of PO2.  The data of figure S2 are consistent 
with a constant b1/PO2 that is independent of PO2, confirmed by a best fit regression 
slope not significantly different from zero (p = 0.422).
The best estimate of the overall consumption constant kcN was estimated from a 
weighted average of the b1/PO2 values in figure S2 that accounts for the fact that the 
confidence in parameter estimates is increased at higher PO2.  The weighted average 
assigned weights in direct proportion to PO2.  The resulting best estimate for kcN was 
0.0186 pmol NO/sec·Torr2.
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Finally, cell number for these experiments was estimated from representative 
measurements of total protein after lysis of cells from the columns, combined with a 
previously established relationship between cell number and protein for RAW 264.7 cells 
(202): 
N = -1.99x104 + 7.09x106(protein)
where protein is in mg. Average cell number for these experiments was 4.9x105.
The overall NO consumption rate constant, normalized to cell number, is 
NO consumption = 0.038  (pmol NO)/(sec·106 cells·Torr NO·Torr O2)
    = 12.7 (mmol NO)/(sec·106 cells·M NO·M O2)
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APPENDIX B: Conversion of kc Units for Comparison to Previous Studies
Thomas et al. reported NO consumption data for cultured rat hepatocytes (251). 
NO consumption was first order in both NO concentration and O2 concentration, with a 
rate constant of 5.38x10-4 M-1·sec-1·(cell/ml)-1.  For an NO solubility at 37°C of 2.13 µM/
Torr (271) and an O2 solubility at 37°C of 1.40 µM/Torr (273), the equivalent rate 
constant in units compatible with our reported value is 1.61 pmol/sec·106 cells·Torr2.
Nalwaya and Deen reported NO consumption data for stimulated RAW 264.7 
cells (190).  NO consumption was treated as first order in NO and zero order in O2, with a 
rate constant of 0.6 sec-1.  They measured NO consumption over a range of PO2. Taking 
as an approximation a PO2 in the middle of this range at 100 Torr, with an NO solubility 
as above, and with their estimate of cell volume of 8.8x10-13 L/cell, the equivalent rate 
constant is 0.011 pmol/sec·106 cells·Torr2.
Gardner et.al. reported NO consumption data for several cell types (81).  NO 
consumption values, in compatible units, ranged from 0.050 to 0.52 pmol/sec·106 
cells·Torr2.
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Figure 1.
Forced convection cell culture system.  Adherent RAW 264.7 cells were cultured at 37°C 
on the inside of a fused-silica column (inset).  The media, delivered by forced convection 
via a roller pump, was partially degassed by prewarming to 40°C, and then was 
equilibrated with calibrated compressed gas mixtures ranging from 0 to 157 Torr O2 (5% 
CO2, balance N2) inside one of two gas equilibrators (labeled Gas Equilibrator 1 and 2). 
Rapid changes in O2 tension or media components were enabled by a switching valve 
upstream from the column of adherent cells (labeled A).  NO in the media stream 
(effluent NO) was measured by an NO electrode (WPI) located downstream from a 
second switching valve (labeled B) that permitted assay of media from the cells or a 
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bypass.  The bypass loop allowed for regular electrode baseline measurements.  A 
syringe pump controlled the delivery of deoxygenated, deionized H2O equilibrated with 
2000 ppm NO (balance N2) into a T connector (labeled T) inserted into the media stream 
from gas equilibrator 2.  The addition of specific NO tensions (input NO) enabled 
calibration of the NO electrode and evaluation of cellular NO consumption. Figure 
adapted from Baumgardner and Otto (6).
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Figure 2.
NO Consumption by Media.  Oxygen dependence of the signal at the NO electrode was 
measured as a function of NO tension in minimal essential media (JBMEM) in the 
absence of cells.  Each bar represents the mean (SD) of the NO probe signal (pA) for 
JBMEM at five input PNO and six PO2 (n = 3).  Because the conversion of NO to its stable 
end products (NO2 and NO3) is O2 dependent, the results imply that NO consumption by 
the media is negligible.
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Figure 3.
Effect of PO2 on NO Production.  A. Representative tracing of NO (ppm) released by 
LPS and IFNγ stimulated RAW 264.7 cells during rapid switching between 0 and 36 Torr 
O2.  Cells were repeatedly exposed to 0 Torr O2 for 2 minutes, then 36 Torr O2 for 3 
minutes for a combined total of 40 minutes (n = 4).  Arrows indicate probe baseline, 
which was measured at the beginning and end of the experiments via the bypass loop.  B. 
Representative tracing from one of five experiments in which LPS and IFNγ stimulated 
RAW 264.7 cells were exposed to eight O2 tensions ranging from < 1 to 157 Torr in a 
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randomized order, while effluent NO (ppm) was measured electrochemically.  In between 
each O2 tension, cells were exposed to 0 Torr O2.  The numerical values above each 
plateau represent the estimated mean cellular PO2.  C. Michaelis-Menten plot.  The 
calculated KmO2 was 22 (SD 6) Torr.  The calculated Vmax was 4.9 (SD 0.4) nmol/min·106 
cells.
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Figure 4.
Effect of O2 tension on iNOS protein concentration.  Representative western blot of SDS-
PAGE gel for inducible nitric oxide synthase (iNOS) in LPS and IFNγ stimulated RAW 
264.7 cells exposed to 6, 36, or 157 Torr O2 for 40 minutes.  iNOS signal was normalized 
to RAF-1, a constitutively expressed protein.  The bar graph presents the mean (SD) of 
the iNOS to RAF-1 ratio at each PO2 (n ≥ 4).  (-) Unstimulated RAW 264.7 cells exposed 
to 36 Torr O2 for 40 minutes.
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Figure 5.
Effect of O2 tension on iNOS dimerization.  A. Western blot of low temperature SDS-
PAGE gel for inducible nitric oxide synthase (iNOS) in LPS and IFNγ stimulated RAW 
264.7 cells exposed to 6, 36, or 157 Torr O2 for 40 minutes.  M = Hi-Mark pre-stained 
molecular weight marker (Invitrogen, Carlsbad CA).  RA = RAW 264.7 cells grown in 
room air.  CL = RAW 264.7 cells cultured in room air and treated with 10 µM 
clotrimazole, an inhibitor of iNOS dimerization (232), for 30 minutes prior to and during 
stimulation with LPS and IFNγ for 8 hours.  Stim = RAW 264.7 cells were unstimulated 
(-) or stimulated (+) for 18 hours with LPS and IFNγ.  Flow = RAW 264.7 cells grown in 
culture dishes (-) or with forced convection (+).  B. Bars represent the mean (SD) of the 
260 kD to 130 kD ratio (n = 3).  * p = 0.003 compared to 36 Torr.  C. Bars represent the 
mean (SD) of the 500 kD to 130 kD ratio (n = 3).  * p = 0.008 compared to 36 Torr.
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Figure 6.
Effect of NO and O2 tension on cellular NO consumption.  A. Representative tracing of 
1400W inhibition of NO produced by LPS and IFNγ stimulated RAW 264.7 cells (n = 
12).  Cells were switched from JBMEM to 100 µM 1400W in JBMEM lacking L-
arginine (labeled 1400W).  Effluent PNO was measured approximately every 10 minutes 
for 2 minutes (labeled NO).  B. Representative tracing showing effluent PNO measured 
during sequential exposure of 1400W-inhibited cells to 40, 79, 160, 319, and 500 ppm 
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input PNO as labeled, and 0 ppm NO (labeled Cell NO; n = 8).  O2 tension was 6 Torr.  C. 
Cellular NO consumption by LPS and IFNγ stimulated RAW 264.7 cells treated with the 
iNOS inhibitor 1400W was measured as a function of O2 and NO tension.  Each bar 
represents the mean (SD) of the ratio of the effluent PNO with cells to the effluent PNO 
without cells for five input PNO and three PO2 (n ≥ 2).  Reference line = 1.  Ratios < 1 = 
net NO consumption.  Ratios > 1 = net NO production.
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Figure S1.
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Dependence of cellular NO consumption on NO tension.  Plots of QαNO(PNOi-PNOe) versus 
PNO for individual columns at 6, 36, or 83 Torr O2.  The lines represent the linear 
regression.
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Figure S2.
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Dependence of cellular NO consumption on PO2.  Plot of b1/PO2 versus PO2 (n ≥ 2), 
where b1 =  the best fit slope of the QαNO(PNOi-PNOe) versus PNO data presented in Figure 
S1.
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Table 1.  NO Consumption in DMEM.
Component % Consumption
DMEM (Gibco) 99.9
GibcoTM essential 
amino acid mixture (1X)
72
NaHCO3 (3700 mg/L) 48
Glucose (4500 mg/L) 36
Glucose (1000 mg/L) 15
NaCl (6400 mg/L) 7
deionized H2O 0
Using the forced convection cell culture system and NO electrode, effluent NO was 
measured in DMEM and select components after a 29 second exposure to 80 ppm input 
NO in the absence of cells and O2.  The signal generated by the exposure of deionized 
H2O at 0 Torr O2 to 80 ppm NO was designated 0% consumption.
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Table 2.  Cell survival in DMEM and JBMEM.
Time (hours)
Media 2 6 18
DMEM (U) 95.1 (2.7) 97.4 (0.9) 90.2 (3.9)
DMEM (S) 94.8 (0.9) 94.5 (1.3) ND
JBMEM (U) 91.2 (4.7) 90.9 (2.3) 88.0 (5.1)
JBMEM (S) 94.0 (0.4) 94.4 (0.5) ND
RAW 264.7 cells were cultured for 2, 6, or 18 hours in DMEM or JBMEM with (S) or 
without (U) stimulation (1 µg/ml LPS and 100 U/ml IFNγ initiated 18 hours prior to 
seeding; n = 3).  Percent survival was measured via Trypan blue staining.  Data are 
presented as mean (SD).  ND = not determined.
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ABSTRACT
Stimulated macrophages produce nitric oxide (NO) via inducible nitric oxide 
synthase (iNOS) using molecular O2, L-arginine, and NADPH.  Exposure of 
macrophages to hypoxia decreases NO production within seconds due to limitation of the 
reactant(s).  Conflicting data exist regarding the effect of pO2 on NADPH production via 
the oxidative pentose phosphate cycle (OPPC).  Therefore, the present studies were 
developed to determine whether NADPH could be limiting for NO production under 
hypoxia.  Production of NO metabolites (NOx) and OPPC activity by RAW 264.7 cells 
was significantly increased by stimulation with lipopolysaccharide (LPS) and interferon γ 
(IFNγ) at pO2 ranging from 0.07% to 50%.  OPPC activity exhibited a linear dependence 
on NOx production at pO2 > 0.13%.  Increased OPPC activity by stimulated RAW 264.7 
cells was significantly reduced by 1400W, an iNOS inhibitor.  OPPC activity was 
significantly increased by concomitant treatment of stimulated RAW 264.7 cells with 
chemical oxidants, hydroxyethyldisulfide or pimonidazole, at 0.07% and 50% O2, 
without decreasing NOx production.  These results are the first to demonstrate the 
relationship between NO production and OPPC activity over a wide range of pO2, and to 
rule out limitations in OPPC activity as a mechanism by which NO production is 
decreased under hypoxia.
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INTRODUCTION
Nitric oxide (NO) production is a key component of the macrophage response 
during inflammation (33, 172).  Macrophages stimulated by pathogen associated 
molecular patterns (PAMPs) produce NO from molecular O2, L-arginine, and NADPH 
via inducible nitric oxide synthase (iNOS) (245).  NO production clearly depends on the 
partial pressure of O2 (pO2) (179, 202, 218), and the estimated cellular KmO2 (14 Torr 
(202) to 77 ± 1.4 Torr (179)) is within the physiological range (5 to 71 Torr (23, 37, 42, 
124, 129, 263, 282)).  Systemic and/or tissue hypoxia develops during several 
inflammatory diseases (42, 75, 122), extending the pO2 range for tissue macrophages to 
even lower levels, and potentially limiting NO production in vivo.  Acute exposures to 
hypoxia have been shown to rapidly (within seconds) and reversibly decrease NO 
production by PAMPs stimulated macrophages without decreasing iNOS protein or 
assembly (218), providing evidence for the dynamic regulation of NO production by 
substrate limitation.  While molecular O2 is clearly limiting, an effect of hypoxia on the 
electron donor NADPH represents a second potential mechanism that has not been 
investigated in macrophages.
NADPH is constitutively produced by NADP+ dependent malic enzyme and 
isocitrate dehydrogenase.  When NADPH oxidation exceeds the capacity of these 
enzymes to reduce the substrate, however, the increase in [NADP+] activates glucose-6-
phosphate dehydrogenase (G6PD), the initial and rate limiting enzyme of the oxidative 
pentose phosphate cycle (OPPC) (68).  An association between NADPH production by 
G6PD and the production of NO has previously been demonstrated in endothelial cells 
(156-158), an insulin-producing pancreatic beta cell line (RINm5F) (98), and 
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macrophages (57, 112, 180, 258).  In macrophages, stimulation with PAMPs was found 
to elicit a parallel increase in OPPC activity (153, 177, 191) and NO production (57), by 
increasing G6PD activity and metabolic flux through the OPPC, rather than via the malic 
enzyme (58).  Moreover, pharmacologic inhibition of OPPC activity or G6PD deficiency 
was shown to significantly impair NO production by stimulated macrophages (112, 180, 
258).
Reduction of NADP+ via the OPPC does not require molecular O2.  Classical 
studies have measured increased [NADPH] in response to short term hypoxia due to the 
absence of metabolically-generated oxidizing agents (99, 127, 227, 259).  More recently, 
however, [NADPH] was found to be significantly decreased in denuded bovine coronary 
arteries following brief exposure to hypoxia (~ 8 to 10 Torr, 20 minutes (100)).  This 
effect was attributed to increased glycolytic flux, resulting in the redirection of substrate 
(glucose-6-phosphate) away from the OPPC.  However, OPPC activity was not directly 
measured in these experiments.  These results suggest NADPH availability may be 
limited during acute hypoxia in some tissues and/or cell types.
NADPH production via the OPPC maintains the cellular redox equilibrium (16). 
Therefore, to investigate whether OPPC activity was limited during acute hypoxia, the 
cells were simultaneously exposed to hydroxyethyldisulfide (HEDS) or pimonidazole 
(PIMO) to pharmacologically induce oxidative stress by two distinct mechanisms.  HEDS 
is a low molecular weight, cell permeable disulfide that is reduced by exchange reactions 
with glutathione and other cellular thiols.  These oxidized cellular thiols are subsequently 
reduced by NADPH-dependent glutathione and thioredoxin reductases (18, 26, 27). 
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PIMO is reduced by cytochrome P450 enzymes, which also utilize NADPH to provide 
reducing equivalents (264).
The primary goal of this study was to investigate the relationship between pO2 
(0.07% to 50%), NO production, and OPPC activity in PAMPs stimulated and 
unstimulated macrophages (Figure 1).  We chose to study RAW 264.7 cells due to the 
extensive literature on the pO2 dependence of NO production in these cells (179, 202, 
218), and due to their abundant and persistent NO production (61).  We hypothesized that 
4 hours of hypoxia would decrease NO production and OPPC activity without affecting 
iNOS concentration or iNOS dimerization.  Second, we hypothesized that pO2 would not 
affect the response of OPPC activity to chemically-induced oxidative stress via HEDS or 
PIMO.  Our results suggest that pO2, and not NADPH availability, affects NO production 
by PAMPs stimulated macrophages during acute hypoxia.
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METHODS
Cell Culture
RAW 264.7 cells (American Type Culture Collection, Manassas, VA) were 
maintained at 37°C 5% CO2 in DMEM (Invitrogen, Carlsbad, CA) supplemented with 
10% FBS (HyClone, Logan, Utah) and 1% antibiotic/antimycotic (penicillin, 
streptamycin, amphotericin B; Invitrogen) for up to 10 passages.  For experiments, 106 
cells were plated on 20 mL glass vials (inner diameter ~ 24 mm), or 1.5 x 106 cells were 
spot platted on 50 mm glass dishes (143).  Glass dishes and vials were cleaned and fired 
at 420°C, then treated with 75 mM sodium carbonate (Fisher, Fair Lawn, NJ) and 15% 
FBS for 1 hour at 37°C, treated with 0.2% gelatin (BioRad, Richmond, CA) for 20 
minutes, and dried under UV light prior to plating the cells.  Cells were then cultured 
overnight with 3 mL of MEM (Invitrogen, 11095) supplemented with penicillin, 
streptomycin, 15% FBS, non-essential amino acids, and 1 mM pyruvate.  Stimulation of 
RAW 264.7 cells was performed by treating cells overnight (at least 18 hours) with 1 µg/
mL LPS (E. coli O111:B4; Sigma) and 100 U/mL CHO-derived recombinant mouse 
IFNγ (Cell Sciences, Canton, MA).  Immediately prior to experiments, the media was 
replaced with 1 mL of low glucose (2 mM) MEM buffered with 25 mM HEPES (i.e. 
instead of sodium bicarbonate to prevent saturation of the filter paper with unlabeled CO2 
during the measurement) and containing 5% FBS, non-essential amino acids, 1% 
penicillin and streptomycin, and 2 mM glutamine.  HEPES-buffered media pH was not 
affected by pO2 or any of the other treatment conditions (data not shown).  Where 
indicated, NOx production was inhibited by treating cells with 100 µM N-[[3-
(aminomethyl)phenyl]methyl]-ethanimidamide, dihydrochloride (1400W; Cayman 
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Chemical, Ann Arbor, MI) in the absence of L-arginine for one and one half hours 
immediately prior to switching to low glucose media.  To chemically induce oxidative 
stress, 2 mM hydroxyethyldisulfide (HEDS) or 2 mM pimonidazole (PIMO) were added 
to the low glucose media.
pO2 Control with Thin Film Cell Culture
RAW 264.7 cells were cultured at 0.07%, 0.13%, 0.24%, 0.61%, 2%, 10%, or 
50% O2 for 4 hours at 37°C in vials or dishes contained in leak proof aluminum 
chambers, which enabled precise control of headspace pO2 as previously described (142-
144, 259).  Briefly, glass vials were capped with a rubber stopper containing a center well 
(Kimble Chase, Vineland, NJ) with a 1 × 0.5 cm Whatman GF/B glass-fiber filter soaked 
with 100 µL 5% KOH (259).  A 25G 5/8 inch needle was inserted into the stopper to 
enable slow gas exchange during the evacuations and pressurizations for oxygen control, 
while limiting gas exchange under the constant pressure conditions during the subsequent 
incubation (259).  Vials or dishes were placed in aluminum chambers and subjected to a 
series of gas exchanges with N2 or O2 to produce the desired headspace pO2.  Chambers 
were warmed to 37°C and shaken continuously to ensure adequate gas exchange between 
the headspace and the media throughout the experiment (4 hours).  The pO2 in the 
chambers was measured at the end of the incubation period using a polarographic oxygen 
electrode.  However, the pO2 in the headspace of each vial was not directly accessible. 
Additionally, the depth of the medium layer in the vials did not conform to the “thin-
layer” model that was originally developed in 50 mm glass dishes (143).  Thus, in 
separate experiments, we added 100 µM EF5 to both dishes and vials, and assayed for 
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EF5 adducts using flow cytometry as previously described (141, 142) in order to directly 
assess cellular pO2.  Note that in the experiments presented, pO2 is defined as the % of 
oxygen in 1 atmosphere of dry gas at 37°C (i.e. 100% = 760 mm of Hg).
  
NOx Measurement
Nitrite, nitrate, and nitrosothiols (NOx) were measured in media or cell lysates by 
injecting 20 µL into a reaction chamber containing a VCl3/HCl mixture (0.4 g VCl3 in 50 
mL 1 N HCl) heated to 90°C.  The resulting NO was continuously flushed with helium 
into a Sievers Nitric Oxide Analyzer 280i (GE Analytical Instruments, Boulder, CO) for 
reaction with ozone and measurement via chemiluminescence.  Quantification was 
performed by comparison to standards prepared with NaNO2.
Electrophoresis and Immunoblotting
Cell lysates were prepared by washing cell monolayers with ice cold cell rinse 
(6.8 g/L NaCl, 400 mg/L KCl, 122 mg/L NaH2PO4 anhydrous, 1 g/L glucose, 25 mM 
HEPES, pH 7.2), and then scraping cells into 0.4 mL ice cold protease-inhibitor 
containing hypotonic lysis buffer (1:1000 Protease Inhibitor Cocktail P8340 (Sigma-
Aldrich, St. Louis, MO), 10 µM phenylmethylsulfonyl fluoride (Sigma-Aldrich) in 
dH2O).  Lysates were subjected to 3 freeze/thaw cycles (-70°C).  Cell lysate protein 
concentration was measured using the Biorad DC protein assay (Hercules, CA).  Proteins 
(5 µg) were separated on a 7.5% Tris-HCl gel using SDS PAGE or low temperature SDS 
PAGE (LT SDS PAGE) as previously described (218), transferred to polyvinylidene 
fluoride (ImmobilonTM-FL 0.45 µm; Millipore, Bedford, MA), and immunoblotted for 
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iNOS (1:2000; NOS2 M19 sc650, Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  β 
actin (1:20,000; Monoclonal anti-β actin Clone AC-15 A5441, Sigma-Aldrich) was used 
as the loading control.  Primary antibodies were immunocomplexed with IRDyeTM 800 
goat anti-rabbit or goat anti-mouse (1:10,000; Rockland, Gilbertsville, PA).  Proteins 
were detected, documented, and analyzed using an Odyssey Imaging System and 
software (LiCor Biosciences, Lincoln, NE).
OPPC and TCA Activity
RAW 264.7 cells were cultured in the presence of 2 mM glucose labeled in either 
the 1-14C or 6-14C position at a specific activity of 200 µCi/mmol glucose in 1 ml of 
bicarbonate-free MEM.  At the completion of each experiment, the vials were removed 
from the aluminum chambers, the needle was removed from the rubber stopper, and 
cellular metabolism was stopped by injection of 100 µL 6 N acetic acid into the media; 
the acidification step also releases CO2 from the medium into the gas phase.  14CO2 was 
collected on a 5% KOH saturated filter overnight at room temperature.  The filter was 
removed and the 14CO2 was counted with a Packard liquid scintillation counter.  TCA 
activity leads to release of 14CO2 from either the 1-14C or 6-14C position of glucose, while 
OPPC activity causes release of 14CO2 only from the 1-14C position.  Thus, OPPC activity 
was calculated using parallel vials and subtracting 14CO2 produced in the presence of 6-
14C glucose from the 14CO2 produced in the presence of 1-14C glucose.
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Statistics
The apparent Km and Vmax values were calculated by SigmaPlot Enzyme Kinetics 
Module 1.1 using a Michaelis-Menten non-linear analysis.  Comparison of means were 
tested by ANOVA for the effect of pO2 on measured values, and by two way ANOVA for 
the effect of pO2 and treatment on measured values.  Data presented are mean ± SD.
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RESULTS
Control of Cellular pO2
Cellular pO2 was regulated using a modified version of the Thin Film Culture 
Method developed in our laboratory (143).  To ensure the modified method (i.e. glass 
vials with rubber stopper and needle) provided the same pO2 at the cellular level, we 
compared the cellular pO2 in glass dishes with the cellular pO2 in glass vials via the 
measurement of EF5 protein adducts (Figure 2).  The formation of EF5-protein adducts 
increases as the pO2 decreases in a quantitative manner, thus permitting an accurate 
measurement of cellular pO2 because the pO2 is constant between the gas and liquid 
phases (143).  The pO2 dependence of EF5 binding for RAW 264.7 cells incubated on 
glass dishes was similar to results from other cultured cell lines (141).  Importantly, the 
EF5 binding for cells in glass vials closely paralleled EF5 binding for cells on glass 
dishes (Figure 2).
pO2 dependence of NOx production
NOx, iNOS protein levels, and iNOS dimerization were measured using the thin 
film cell culture method and low glucose media required for the OPPC measurements. 
The results obtained in low glucose media were similar to previous cell culture systems 
(Figure 3 and references (202, 218)).  Cumulative NOx released into the media by LPS 
and IFNγ-stimulated RAW 264.7 cells fit a Michaelis-Menten kinetic model with a KmO2 
of 0.66 ± 0.12 % (5 ± 1 Torr) and a Vmax of 25.2 ± 1.0 nmol/106 cells (R2 = 0.91, Figure 
3A).  NOx measured in cell lysates from LPS and IFNγ-stimulated RAW 264.7 cells 
exposed to 50% O2 for 4 hours was 3.5 ± 1.1 nmol/106 cells, 13% of NOx detected in the 
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media.  In the absence of LPS and IFNγ stimulation, RAW 264.7 cells did not produce 
detectable NOx (data not shown).  pO2 did not alter iNOS protein concentration (Figure 
3B) or iNOS dimerization (Figure 3C).  Stimulation of RAW 264.7 cells with LPS and 
IFNγ decreased total protein isolated from the vials by 30%, consistent with previous 
reports (200, 218).  pO2 alone did not affect cell adhesion as visualized by light 
microscopy, or the amount of total protein isolated from the vials (data not shown).
pO2 dependence of OPPC Activity
Unstimulated RAW 264.7 OPPC activity exhibited a biphasic response to pO2 
(Figure 4A), with a decrease between 0.07% and 2% O2 and a 2.5 fold increase between 
10% and 50% O2.  Stimulation of RAW 264.7 cells with LPS and IFNγ for 18 hours 
significantly increased OPPC activity at all pO2 (p < 0.001).  OPPC activity correlated 
directly with NOx production for pO2 greater than 0.13% O2 in LPS and IFNγ stimulated 
cells (Figure 4B).  Treatment of LPS and IFNγ stimulated RAW 264.7 cells with 1400W, 
an iNOS inhibitor, completely inhibited NOx production (Table 1), and significantly 
decreased OPPC activity to levels observed without LPS and IFNγ treatment (p < 0.001; 
Figure 4A, Table 1).  1400W also decreased OPPC activity in unstimulated RAW 264.7 
cells (Table 1) and unstimulated RAW 264.7 cells treated with PIMO (data not shown) at 
50% O2, but not 2% and 0.07% O2, suggesting possible nonspecific effects of the 
treatment at 50% O2.  Treatment of RAW 264.7 cells with LPS and IFNγ decreased TCA 
activity (Table 1), consistent with NOx-mediated respiratory inhibition (reviewed by 
(40)).  Treatment with 1400W, however, did not reverse the observed affect on TCA 
activity at any pO2 (Table 1).
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OPPC Challenge with HEDS and PIMO
To further increase oxidative challenge, RAW 264.7 cells were treated with 
HEDS or PIMO, two chemical oxidants, which operate by distinct mechanisms.  HEDS 
or PIMO both increased OPPC activity significantly in RAW 264.7 cells at either 0.07% 
O2 and 50% O2 (p < 0.001, Figure 5).  Stimulation of RAW 264.7 cells with LPS and 
IFNγ did not alter the magnitude of the increase in OPPC activity induced by HEDS or 
PIMO treatment.  NOx production was measured during OPPC challenge to determine 
whether NO production was maintained despite chemical oxidant stress (i.e. to assess 
whether OPPC capacity was able to accommodate both processes).  NOx production by 
LPS and IFNγ stimulated RAW 264.7 cells was not affected by HEDS treatment at 
0.07% O2 or 50% O2 (Figure 6).  PIMO, a nitroimidazole, was detected by the nitric 
oxide analyzer (2 mM PIMO in media generated the equivalent signal of 3.6 µM 
NaNO2).  Even after correcting for this signal, however, NOx measurements were 
significantly increased in PIMO treated LPS and IFNγ stimulated RAW 264.7 cells at 
0.07% O2 (p < 0.05) and 50% O2 (p < 0.001), suggesting PIMO might be metabolized to 
nitrite, nitrate, or nitrosothiols (178).
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DISCUSSION
Increased NOx production and increased OPPC activity were observed over a 
wide range of pO2 (0.07% to 50% O2) in LPS and IFNγ stimulated RAW 264.7 cells, 
consistent with previous reports of a relationship between NO production and NADPH 
oxidation in atmospheric O2 (57, 98, 112, 156-158, 180, 258).  Moreover, inhibition of 
NO production significantly decreased OPPC activity at all pO2 investigated, suggesting 
that the majority of the increased OPPC activity observed in stimulated RAW 264.7 cells 
was directly related to NO and/or reactive nitrogen species production.  Hypoxia did not 
inhibit the ability of the OPPC to respond to chemically mediated oxidative stress 
induced by HEDS or PIMO, and HEDS did not inhibit NOx production in stimulated 
cells.  These results demonstrate that OPPC activity is not limiting for NO production by 
stimulated RAW 264.7 cells irrespective of pO2.
The pO2 dependence of NOx production was well fit by a Michaelis-Menten 
model, and the measured KmO2 (0.66% or 5 Torr) was within the range reported 
previously (5 Torr to 96 Torr) (1, 67, 179, 202, 214, 218).  Despite substantial differences 
in experimental methodology, these data are consistent with our previous results using 
forced convection cell culture (22 Torr) (218), and our previous data from cell 
monolayers grown in dishes for 18 hours, after correction for iNOS activity and media 
depth (14 Torr) (202).  The data are also consistent with measurements made by 
Rengasamy and Johns using RAW 264.7 cell lysates and a steady state system (5 Torr) 
(214).  In contrast, rapid equilibrium studies with recombinant iNOS reported apparent 
KmO2 values of 93 Torr (1) and 96 Torr (67).  At present, the reasons underlying the > 10 
fold higher apparent KmO2 measured with recombinant iNOS are unclear.  Regardless, the 
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range of pO2 found in vivo (5 to 71 Torr (23, 37, 42, 75, 122, 124, 129, 263, 282)) has the 
potential to significantly and rapidly affect NO production, as suggested previously (1, 
67, 179, 202, 214, 218).
The pO2 dependence of NOx production was not due to changes in iNOS protein 
levels or iNOS dimerization, consistent with our previous studies of short-term hypoxia 
(40 minutes) (218).  Multiple studies have documented the affects of long-term (18 to 24 
hours) hypoxia on iNOS upregulation via HIF 1α (126, 181, 182).  Increased expression 
of iNOS protein due to hypoxia, however, requires incubations greater than or equal to 6 
hours (4).  The half-life of iNOS in atmospheric O2 is approximately 1.6 hours (145), but 
the effect of hypoxia on stability of the protein has not been investigated.  Based on the 
present study, we conclude that short-term hypoxia (i.e. < 4 hours) has negligible effects 
on the balance between transcription, translation, assembly, and degradation of iNOS.
Several previous studies have investigated the effects of short term hypoxia on 
NADPH and/or OPPC activity (99, 100, 127, 227, 259), but we have found no prior 
studies that examined the pO2 dependence of OPPC activity in macrophages. 
Interestingly, OPPC activity in unstimulated RAW 264.7 cells exhibited a biphasic pO2 
dependence in contrast to our previous work in HT1080 (human fibrosarcoma) and A549 
(human lung carcinoma) cells (259).  One potential source of NADP+ under hypoxia is 
the mitochondrial transhydrogenase.  The decrease in mitochondrial respiration observed 
under severe hypoxia results in elevated glycolytic flux, to maintain [ATP].  Hypoxic 
glycolysis produces lactate and NAD+.  Mitochondrial transhydrogenase couples 
reduction of NAD+ to oxidation of NADPH (128).  This reaction has been shown to 
increase under anaerobic conditions (241).  We propose that the NADP+ produced by the 
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mitochondrial transhydrogenase catalyzed reaction resulted in the stimulation of OPPC 
activity that we observed under hypoxia.  While we are examining this hypothesis more 
thoroughly, it is important to note that the increase of OPPC activity between 2% and 
0.07% for unstimulated RAW 264.7 cells under hypoxia, though statistically significant, 
is relatively small compared to the increase observed between 10% and 50% O2, or 
compared to the increase observed in LPS and IFNγ stimulated cells.
Stimulation of RAW 264.7 cells with LPS and IFNγ significantly increased OPPC 
activity at all pO2, thus extending previous reports for PAMPs stimulated macrophages in 
atmospheric O2 (58, 153, 191, 192).  These results are consistent with our results 
previously obtained in tumor cells (259), and conform with the classical view of 
decreased metabolic flux through the OPPC under hypoxia (99, 127, 227), whereby 
removal of O2 leads to a reducing environment.  For example, Scholz et al. measured an 
increase in NADPH fluorescence in rat liver within seconds of exposure to near anoxic 
pO2, and measured a new steady state within minutes (227).  Treatment with the iNOS 
inhibitor, 1400W, significantly reversed the affect of LPS and IFNγ stimulation at all 
pO2, suggesting the increase in OPPC activity was to accommodate NO production 
and/or the neutralization of reactive nitrogen mediated stress.  Although NADPH may 
also be consumed by NADPH oxidase (149), or even by iNOS to produce superoxide 
(247), superoxide release by LPS and IFNγ stimulated RAW 264.7 cells is reported to 
only occur within the first hour after stimulation (203), and to be only 6 % of NO 
production (11, 190).
OPPC activity correlated linearly with NOx production above 0.13% O2, with a 
slope of approximately 2, suggesting that for each molecule of NOx measured, 4 
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molecules of NADPH were consumed.  NO production is reported to require 1.5 
molecules of NADPH per NO molecule (reviewed by (247)), leaving a theoretical excess 
of 2.5 NADPH molecules.  One possibility for this excess is that NADPH is required to 
maintain cellular redox equilibrium in the presence of reactive oxygen and nitrogen 
mediated stress (reviewed by (16, 73)).  Another possibility is a limitation associated with 
our measurements: NOx does not account for all NO metabolites, or for the NO released 
into the gas phase of the vial.  Since the thin film culture system is designed to keep the 
gas phase in equilibrium with the liquid phase, it is not technically possible to confine 
NO to the media.  Because NO production was not measured via radiolabeled L-arginine, 
it is impossible to calculate the amount of NO released into the gas phase.  Therefore, the 
absolute relationship between NO, NOx production, and NADPH consumption remains 
to be addressed by additional studies.
Because OPPC activity decreased with pO2, we investigated whether OPPC 
activity was limited by hypoxia.  HEDS and PIMO are chemical oxidants that induce 
oxidative stress by mechanisms that are not dependent on pO2 (18, 26, 27, 264).  Thus, 
these compounds were used to challenge the OPPC in RAW 264.7 cells under hypoxia. 
Treatment with HEDS or PIMO significantly increased OPPC activity under all 
conditions tested including hypoxia.  To further investigate the relationship between 
OPPC activity and NOx production, we measured NOx production in LPS and IFNγ 
stimulated RAW 264.7 cells exposed to HEDS, and found that NOx production was 
maintained despite this chemical challenge to the OPPC.  Therefore, we conclude that 
OPPC activity is not limiting for NO production in stimulated RAW 264.7 cells.
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In summary, OPPC activity was increased following stimulation with LPS and 
IFNγ at all pO2 investigated in RAW 264.7 macrophages, a response which appears to be 
a direct consequence of NO production.  OPPC activity under conditions of chemically 
mediated oxidative stress (i.e. HEDS or PIMO treatment) was not limited by hypoxia, nor 
was it limiting for NO production under any of the conditions investigated.  Finally, we 
conclude that O2 substrate limitation is the primary mechanism responsible for decreased 
NO production by LPS and IFNγ stimulated macrophages exposed to acute hypoxia.
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Figure 1.
Schematic of the relationship investigated between NOx production and OPPC activity. 
The production of 1 molecule of NO consumes 1.5 NADPH molecules (247).  The NO 
metabolites (NOx) measured in this study include nitrite, nitrate, and nitrosothiols in the 
extracellular media (see Methods).  The OPPC produces 2 molecules of NADPH per 
molecule of CO2 released.  OPPC activity was measured as the production of 14CO2 from 
14C-labeled glucose minus the 14CO2 produced by the TCA cycle (see Methods).
70
Figure 2.
EF5 binding in Glass Dishes versus Vials.  RAW 264.7 cells were cultured for 3 hours in 
the presence of 100 µM EF5 at 0.03%, 0.14%, 0.21%, 0.59%, 1.04%, 1.91%, or 11.7% 
O2.  RAW 264.7 cells were labeled with an EF5-specific Cy5 antibody and EF5 binding 
was measured by flow cytometry of a single cell suspension.  Results across experiments 
were normalized to a positive control.  Note that in the experiments presented, pO2 is 
defined as the % of oxygen in 1 atmosphere of dry gas at 37°C (i.e. 100% = 760 mm of 
Hg).
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Figure 3.
NOx production, iNOS protein concentration, and iNOS dimerization in LPS and IFNγ 
stimulated RAW 264.7 cells cultured with Thin Film Cell Culture.  LPS and IFNγ 
stimulated RAW 264.7 cells were exposed to 0.07%, 0.13%, 0.24%, 0.61%, 2%, 10%, or 
50% O2 (balance N2) for 4 hours using Thin Film Cell Culture.  A. Media NOx were 
converted to NO via reaction with vanadium chloride and measured with a Sievers Nitric 
Oxide Analyzer (see Methods).  Data presented are mean ± SD. (n ≥ 3).  B, C. 
Representative western blots of an SDS-PAGE gel (B) and a low temperature SDS-
PAGE gel (C) for iNOS and β actin. (n ≥ 3).  (R) RAW 264.7 cells grown in atmospheric 
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O2.  (+) RAW 264.7 cells treated with LPS and IFNγ for at least 18 hours prior to 
exposure to the designated pO2.  (-) RAW 264.7 cells not treated with LPS and IFNγ. 
(M) BioRad Kaleidoscope Prestained Standards (BioRad, Hercules CA).
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Figure 4.
Correlation between OPPC activity and NOx production.  A. RAW 264.7 cells (closed 
circles), LPS and IFNγ stimulated RAW 264.7 cells (open circles), or LPS and IFNγ 
stimulated RAW 264.7 cells pretreated with the iNOS inhibitor, 1400W at 100 µM (open 
triangles) were incubated with 1-14C glucose or 6-14C glucose in parallel experiments at 
0.07%, 0.13%, 0.24%, 0.61%, 2%, 10%, or 50% O2 (balance N2).  Cumulative OPPC 
activity was calculated by subtracting 14CO2 produced in the presence of 6-14C glucose 
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(TCA Activity) from 14CO2 produced in the presence of 1-14C glucose (OPPC Activity + 
TCA Activity).  OPPC activity by LPS and IFNγ stimulated RAW 264.7 cells was 
significantly different from RAW 264.7 cells and LPS and IFNγ stimulated RAW 264.7 
cells + 1400W at all pO2 (p < 0.001).  At this concentration (100 µM), 1400W did not 
completely inhibit the enhanced OPPC activity resulting from LPS and IFNγ stimulation. 
Data presented are mean ± SD. (n ≥ 4)  B. Linear regression of OPPC activity and NOx 
production (data shown in Figure 2).  y = [b1]x + [b0]
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Figure 5.
OPPC Challenge with HEDS and PIMO.  OPPC activity of RAW 264.7 cells and LPS 
and IFNγ stimulated RAW 264.7 cells was measured during treatment with one of two 
chemical oxidants, HEDS (2 mM) or PIMO (2 mM), at 0.07% and 50% O2 for 4 hours. 
(*) Significant effect of HEDS or PIMO treatment on OPPC activity versus no treatment 
(p < 0.001).  Data presented are mean ± SD. (n = 4) 
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Figure 6.
NOx production during OPPC challenge with HEDS and PIMO.  RAW 264.7 cells and 
LPS and IFNγ stimulated RAW 264.7 cells were treated with 2 mM HEDS or 2 mM 
PIMO during a 4 hour exposure to 0.07% or 50% O2.  Media NOx were converted to NO 
via reaction with vanadium chloride and measured with a Sievers Nitric Oxide Analyzer. 
PIMO data were corrected for the signal of PIMO in media (3.64 nmol).  A statistically 
significant effect of HEDS or PIMO on NOx versus no treatment was calculated where 
indicated (* p < 0.05, ** p < 0.001).  Data presented are mean ± SD. (n ≥ 3).
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Table 1.  Effect of 1400W on RAW 264.7 NOx Production, OPPC activity, and TCA 
activity.  
% pO2 0.07 0.07 2 2 50 50
1400W - + - + - +
NOx
nmol/106 cells
NS 1.5 ± 2.1 ND 0.1 ± 1.1 ND 0.2 ± 0.3 ND
S 4.9 ± 3.0 * 0.0 ± 0.5 † 15.5 ± 2.8 * ND 26.4 ± 1.5 * 0.3 ± 1.3 †
OPPC
nmol CO2/106 cells
NS 14.7 ± 3.8 ‡ 10.7 ± 1.7 7.4 ± 0.9 5.0 ± 1.9 25.1 ± 7.9 ‡ 9.7 ± 1.0 §
S 25.0 ± 2.2 a 13.1 ± 0.4 b 59.0 ± 4.8 a 18.8 ± 1.9 a,b 71.8 ± 7.3 a 27.9 ± 5.3 a,b
TCA
nmol CO2/106 cells
NS 0.3 ± 0.1 0.2 ± 0.02 1.7 ± 0.4 4.9 ± 0.4 c 4.1 ± 2.9 5.78 ± 2.9
S 0.4 ± 0.1 0.3 ± 0.01 0.6 ± 0.04 0.3 ± 0.04 d 0.6 ± 0.04 d 0.3 ± 0.1 d
RAW 264.7 cells were stimulated (S), or not (NS), with 1 µg/mL LPS and 100 U/mL 
IFNγ prior to exposure to 4 hours of 0.07%, 2%, or 10% O2 with Thin Film Cell Culture. 
RAW 264.7 cells were treated with 100 µM 1400W (+), or not (-), for 1 ½ hours prior to 
Thin Film Cell Culture.  (ND) = not determined.  (*) Effect of LPS and IFNγ treatment 
on media NOx (0.07% p < 0.05; 2% and 50% p < 0.001).  (†) Effect of 1400W treatment 
on media NOx (0.07% p < 0.01, 50% p < 0.001).  (‡) Effect of pO2 on RAW 264.7 OPPC 
activity (0.07% and 50% > 2%, p < 0.05).  (§) Effect of 1400W treatment on RAW 264.7 
cells OPPC activity (p < 0.001).  (a) Effect of LPS and IFNγ treatment on OPPC activity 
(p < 0.001).  (b) Effect of 1400W treatment on OPPC activity by LPS and IFNγ 
stimulated RAW 264.7 cells (p < 0.001). (c) Effect of 1400W on TCA activity (p < 0.05). 
(d) Effect of LPS and IFNγ treatment on TCA activity (Without 1400W p < 0.01, With 
1400W p < 0.001).  Data presented are mean ± SD. (NOx n ≥ 3, OPPC n ≥ 4, TCA n ≥ 
2).
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CHAPTER 3.
EFFECT OF CHANGING EXTRACELLULAR L-ARGININE 
CONCENTRATION ON MACROPHAGE NO PRODUCTION
Mary A. Robinson
Unpublished Data
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INTRODUCTION
L-arginine is a substrate for NO production by iNOS; the nitrogen in NO is 
derived from either of the guanidino nitrogens of L-arginine (120, 206).  Pharmacological 
inhibition of iNOS can be obtained in vivo and in vitro with 1400W, an L-arginine analog 
that contains an amidine and an amine substituted for the guanidino groups (82).  Once 
1400W binds to the L-arginine binding site, it is slowly reversible with a dissociation 
constant (Kd) of 7 nM (82).  L-arginine competes directly with 1400W binding to iNOS 
with a binding constant (Ks) of 2.2 µM (82), similar to the iNOS apparent Km for 
arginine (2.8 µM (245)).  The concentration of L-arginine in the cell culture media used 
for our studies was 300 (JBMEM) and 700 µM (MEM).  Therefore, in the studies 
describe in Chapters 1 and 2, incubations with 1400W were performed in media prepared 
without L-arginine to optimize inhibition kinetics.  Inhibition of NO production by 
exposure to 1400W (100 µM) in media prepared without L-arginine was measured 
directly in the forced convection cell culture system (Chapter 1, Figure 6B).  To 
differentiate the effect of 1400W on NO production from the effect of changing the 
extracellular L-arginine concentration, NO production was also measured in real time 
during exposure to L-arginine deficient media.  This experiment revealed some 
interesting kinetics of L-arginine removal and replacement.
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METHODS
RAW 264.7 cells (American Type Culture Collection, Manassas, VA) were 
cultured using the forced convection cell culture system described in Chapter 1 Methods 
(22).  Cells were stimulated overnight (18 to 24 hours) with 1 µg/ml LPS (E. coli 
O111:B4; Sigma) and 100 U/ml CHO-derived recombinant mouse IFNγ (Cell Sciences, 
Canton, MA).  Then, cells were perfused with a minimal essential media (JBMEM: 140 
mM NaCl, 1.4 mM CaCl2, 5.3 mM KCl, 4.4 mM Dextrose, 25 mM HEPES, 0.3 mM L-
arginine, and 0.1% heat-inactivated FBS (LONZA)) and NO production was measured 
with an NO electrode as described in Chapter 1 Methods.  Once baseline NO production 
was established, the cells were perfused with L-arginine deficient media (JBMEM 
without L-arginine) for 1 hour.  The cells were returned to L-arginine replete media, and 
the effect on NO production was measured.  The pO2 for these experiments was 36 Torr 
O2.
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RESULTS AND DISCUSSION
Perfusing the cells with L-arginine deficient media decreased NO production, but 
did not eliminate it (Figure 1).  NO production achieved a new steady state within 15 
minutes at approximately 20% of the initial NO production level.  One hour later, when 
the cells were returned to L-arginine replete media, NO production immediately (within 
seconds) recovered to the initial measured level (Figure 1).
These results suggest that the majority of the L-arginine utilized for NO 
production by LPS and IFNγ stimulated RAW 264.7 cells was transported into the cell, 
and are consistent with previous observations of extracellular L-arginine usage for NO 
production by some cell types and tissues (171, 294).  They also indicate that transport 
into the cell was fast (within seconds), relative to the rate of intracellular L-arginine 
metabolism (minutes).  MCAT-2B, a member of the cationic amino acid transporter 
family, is upregulated by LPS stimulation of macrophages (52, 53), making this 
transporter a possible candidate for mediating the L-arginine influx.  The forced 
convection cell culture system could be a useful tool to investigate possible MCAT-2B 
involvement, and the potential requirement for extracellular L-arginine.
One limitation of this experiment is that the L-arginine deficient media contained 
0.1% FBS.  Plasma concentrations of L-arginine are typically 50 to 200 µM (286), and 
could explain the residual NO production observed; residual NO production was ~ 75 
nM, and L-arginine concentration due to the addition of 0.1% FBS is estimated to be as 
high as 200 nM.  However, intracellular conversion of L-citrulline to L-arginine via 
argininosuccinate synthase and argininosuccinate lyase is also possible (186, 187).  These 
experiments need to be repeated in media without L-arginine or FBS to evaluate the 
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contribution of intracellular L-arginine supply to NO production by LPS and IFNγ 
stimulated RAW 264.7 cells.
The effect of hypoxia on the kinetics of L-arginine transport and metabolism was 
not investigated.  Hypoxia has also been shown to upregulate MCAT-2B mRNA (169), 
which would theortically increase L-arginine influx.  In contrast, both hypoxia (24 hours) 
alone and in combination with LPS has been shown to upregulate macrophage arginase 
(7, 169), which has been proposed to compete with iNOS for L-arginine as a substrate 
(48, 108, 250).  Inhibition of arginase can increase NO production by stimulated 
macrophages, and vice versa (109).  However, IFNγ stimulation of RAW 264.7 cells did 
not induce arginase (270), and costimulation of RAW 264.7 cells with LPS and IFNγ 
prevented arginase upregulation by an unknown mechanism (270).  Thus, minimal 
arginase should have been present in RAW 264.7 cells following overnight stimulation 
with LPS and IFNγ as described for this experiment and in Chapters 1 and 2.
The duration of hypoxia required to upregulate arginase, and the effect of 
combined stimulation with LPS, IFNγ, and hypoxia on arginase expression and activity, 
have not been investigated.  Because maximal arginase mRNA and protein upregulation 
by LPS (240, 270), cAMP (188), and dexamethasone (188) requires approximately 12 
hours, it is unlikely that the hypoxic exposures used in our experiments (Chapter 1: 40 
minutes; Chapter 2: 4 hours) were long enough to elicit an increase in arginase. 
Furthermore, L-arginine is required for iNOS dimerization, which was either increased 
(Chapter 1) or maintained (Chapter 2) with hypoxia in our experiments.  Therefore, L-
arginine availability for iNOS does not appear to be compromised by arginase in the 
experiments described in Chapters 1 and 2.
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In summary, these data suggest that NO production predominantly depended on 
the continuous transport of extracellular L-arginine into the cell, and that the rate of 
transport was faster than the rate of utilization under these conditions.  Although the 
effects of hypoxia on L-arginine transport and metabolism were not investigated, the 
maintenance of iNOS dimerization in Chapters 1 and 2 implied that L-arginine 
availability for iNOS was not affected by acute hypoxia.  Further study of the 
mechanisms and kinetics of L-arginine transport and metabolism by macrophages in the 
forced convection cell culture system could help elucidate the physiology of L-arginine 
supply for NO production.
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Figure 1.
Effect of Changing Extracellular L-Arginine Concentration on Macrophage NO 
production.  Representative tracing of NO production by LPS and IFNγ stimulated RAW 
264.7 cells exposed to L-arginine deficient media (* 240 seconds), and then returned to 
L-arginine replete media (* 3980 seconds) using the forced convection cell culture 
system.  NO production was continuously measured via an NO electrode; arrows on the x 
axis indicate probe baseline checkpoints.  Data were baseline corrected.  N = 2.
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DISCUSSION
Acute Hypoxic Regulation of NO Production
The ability of macrophages to migrate to sites of infection, injury, and disease 
results in their exposure to multiple pO2 [Physiological: 5 to 71 Torr (23, 32, 37, 42, 87, 
88, 124, 129, 159, 253, 254, 263, 266, 281, 282); Pathophysiological: 0 to 20 Torr (37, 
38, 69, 70, 72, 79, 111, 116, 118, 122, 130, 166, 194, 213, 236, 237)].  Thus, 
macrophages are required to operate over a much wider range of pO2 than most cell 
types.  The studies presented herein are the first to demonstrate the rapidity (seconds) at 
which NO production is affected by changes in pO2, the reversible nature of those 
changes, and confirm that these changes are occurring within the physiological and 
pathophysiological range.  This rapid and reversible decrease in NO production following 
exposure to acute hypoxia (≤ 4 hours) is due to O2 substrate limitation, and not effects on 
iNOS concentration, iNOS dimerization, NADPH availability, or L-arginine availability.
No previous cell culture studies have investigated NO production during acute 
hypoxia for direct comparison to these results.  The measured apparent KmO2 values 
(Chapter 1: 22 ± 6 Torr (218), Chapter 2: 5 ± 1 Torr), however, are within the range of 
values reported previously for long term hypoxic exposures ( ≥ 18 hours) of LPS and 
IFNγ stimulated macrophages (14 Torr (202), 77 ± 1.4 Torr (179)), and for the isolated 
iNOS enzyme (5 ± 0.6 Torr (214), 93 Torr (1), 96 Torr (67)).  They are also well within 
the range of pO2 required for the regulation of NO production in vivo (0 to 71 Torr (23, 
32, 37, 38, 42, 69, 70, 72, 79, 87, 88, 111, 116, 118, 122, 124, 129, 130, 159, 166, 194, 
213, 236, 237, 253, 254, 263, 266, 281, 282).  The rapidity and reversibility of the 
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response within the physiological and pathophysiological pO2 range suggests that 
changes in tissue pO2 in vivo will significantly affect macrophage NO production, as has 
been suggested previously (1, 67, 179, 202, 214).    
Two prior studies investigated the effects of long term hypoxic exposures on 
nitrite production by RAW 264.7 cells concurrently stimulated with LPS and IFNγ (179, 
202).  McCormick et al. measured an apparent KmO2 for the headspace gas of 10.8 ± 2.0 
% (77 ± 1.4 Torr) (179).  Otto and Baumgardner measured a similar pO2 dependence in a 
comparable system, but did not calculate an apparent KmO2 from the nitrite data directly 
(202).  Instead, they measured iNOS protein concentration and activity, and found that 
iNOS protein concentration and activity also decreased as pO2 decreased.  Thus, the 
changes in nitrite were reflective of changes in the specific activity and/or the amount of 
active iNOS, as well as effects due to substrate limitation.  After normalizing nitrite 
production to changes in iNOS activity, and accounting for the O2 diffusion gradient from 
the headspace gas to the cell surface, the estimated apparent KmO2 at the cell surface was 
14 Torr (202), similar to the apparent KmO2 values measured in these studies of acute 
hypoxia (Chapter 1: 22 ± 6 Torr (218), Chapter 2: 5 ± 1 Torr).
Acute hypoxia did not affect iNOS protein concentration, and iNOS dimerization 
was either increased (Chapter 1) or maintained (Chapter 2).  These results are consistent 
with a previous study showing that costimulation with LPS and hypoxia requires a 
minimum of 3 hours and 6 hours to affect iNOS mRNA and protein, respectively (4). 
Therefore, the key difference between the regulation of NO production by acute hypoxia 
and long term hypoxia appears to be the absence of sufficient time for acute hypoxia to 
influence iNOS mRNA and protein concentration.  The mechanism for increased iNOS 
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dimerization observed in cells cultured with forced convection is not known.  Regardless, 
decreased NO production despite increased iNOS dimerization further suggests that 
substrate limitation is the primary mechanism mediating decreased NO production during 
acute hypoxia.
O2 substrate limitation, not decreased NADPH or L-arginine availability, is the 
primary mechanism mediating decreased NO production during acute hypoxia. 
Macrophage OPPC activity linearly correlated with NO production at all pO2, consistent 
with previous studies in atmospheric O2 (58, 153, 191, 192).  OPPC activity was 
decreased during acute hypoxia due to the absence of NO production; treatment with 
1400W, a specific iNOS inhibitor, significantly reduced OPPC activity in LPS and IFNγ 
stimulated macrophages at all pO2.  Chemically mediated oxidative stress (HEDS or 
PIMO) significantly increased OPPC activity under all conditions tested including 
hypoxia, and did not affect NO production (HEDS).  These results are consistent with our 
measurements in tumor cells (259), and conform with the classical view of decreased 
metabolic flux through the OPPC under hypoxia (99, 127, 227), whereby removal of O2 
leads to a reducing environment.  They additionally demonstrate that the absence of 
molecular O2 is not limiting for OPPC activity.
The affect of hypoxia on L-arginine transport and metabolism was not measured 
directly.  However, L-arginine is required for iNOS dimerization (20).  Thus, the increase 
(Chapter 1) or maintenance (Chapter 2) of iNOS dimerization measured in these studies 
suggests L-arginine was not limiting.  These results were expected, because the 
concentration of L-arginine in the media used for these studies (JBMEM: 300 µM, MEM: 
700 µM) was much greater than the L-arginine apparent Km (3 µM) (245).  Interestingly, 
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the removal of L-arginine also rapidly and reversibly decreased NO production to 20% of 
basal levels (Chapter 3).  NO production decreased more slowly upon the removal of L-
arginine (minutes) than upon the removal of O2 (seconds), also suggesting the hypoxia 
mediated decrease in NO production was not due to limited L-arginine influx.  In 
contrast, restoration of L-arginine immediately (seconds) enabled NO production to 
resume at levels equivalent to the initial measured level.  The forced convection cell 
culture system promises to be a useful tool for studying the effect of changes in 
extracellular L-arginine transport on NO production.
In summary, changes in physiological and pathophysiological pO2 rapidly and 
reversibly regulate macrophage NO production via O2 substrate limitation.  Acute 
hypoxia did not alter iNOS protein concentration, increased or maintained iNOS 
dimerization, and did not limit NADPH availability.  Because long term hypoxic 
exposure mediates changes in NO production via effects on iNOS protein in addition to 
substrate limitation, identifying the degree and duration of hypoxia in vivo will be critical 
to assessing its influence on physiological and pathophysiological macrophage NO 
production.
Implications for Macrophage NO Physiology and Pathology
Several macrophage phenotypes produce NO (14, 102, 210, 233, 234), and NO 
production is essential for eliminating certain types of bacterial and parasitic infections 
(6, 94, 96, 215, 265).  However, tissue pO2 varies widely, and tissues become hypoxic in 
the wound environment, and during many inflammatory diseases such as sepsis and 
cancer (116, 194, 213, 236).  The studies presented herein suggest that NO production by 
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macrophages will be rapidly limited by low pO2 in vivo.  Additionally, changes in 
extracellular L-arginine could rapidly affect macrophage NO production in vivo.
The center of the wound environment is hypoxic and depleted of L-arginine (7, 
225).  NO production and L-arginine metabolism by wound macrophages are affected by 
hypoxia.  During hypoxia, wound macrophages metabolize L-arginine by arginase 
instead of iNOS (7).  This switch is thought to mediate the transition from the 
inflammatory phase of wound healing to the proliferative phase (99).  However, once 
angiogenesis and revascularization restore O2 to the wound, redirection of L-arginine 
back to iNOS may result in overlap of the inflammatory phase and the proliferative 
phase, as has been proposed previously (105).  Spatial and temporal measurements of 
tissue pO2, NO production, and angiogenesis during wound healing would provide further 
insight into the sequence, duration, and overlap of these events.
Sepsis is by definition a systemic inflammatory response to infection (36), and 
can be thought of as a systemic wound.  iNOS expressing macrophages in the heart, lung, 
liver, and kidney have been observed via immunohistochemistry during the first 24 hours 
in a rat endotoxemia model (44), which is similar to when of iNOS expressing 
macrophages appear in a localized wound (24 to 72 hours) (211).  Also similar to the 
wound environment, septic patients become hypoxic (118), and L-arginine plasma 
concentrations decrease (78), albeit by different mechanisms.  The results described 
herein suggest that macrophage NO production may be limited in septic patients due to 
decreased O2 and L-arginine availability, as previously proposed (1, 7, 41, 62, 67, 94, 
168, 179, 202, 214, 219).  Spatial and temporal measurements of pO2, NO production, 
and L-arginine concentration and turnover in septic models and/or patients are necessary 
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to verify these results in vivo.  If these findings are confirmed, diminished macrophage 
function as a result of hypoxia and L-arginine depletion could promote overwhelming 
infection, making it questionable as to whether specific iNOS inhibitors will provide 
therapeutic value for patients in septic shock.  Preventing circulatory collapse, while 
enabling macrophages to fight off the infection, may be a more appropriate therapeutic 
strategy for patients in the later stages of sepsis.
Chronic inflammation and hypoxia correlate with tumor development and 
progression (37, 38, 69, 70, 79, 111, 162, 166).  The results herein suggest that 
macrophage, and possibly tumor, NO production will be rapidly and reversibly limited 
within hypoxic areas.  Similar to wound macrophages, TAM in a hypoxic environment 
may preferentially metabolize L-arginine via arginase (7).  Arginase production of 
ornithine promotes cell growth, and may enable tumor growth (184).  Furthermore, the 
results herein suggest that NO production could be restored once angiogenesis improves 
O2 delivery to the tumor.  Thus, spatial and temporal measurements of pO2, NO 
production, and ornithine production, and identification of the cell types involved, are 
needed to verify these results in vivo, and could further our understanding of how these 
factors contribute to tumor progression and metastasis.
Conclusions
The pO2 dependence of NO production occurs within the physiological and 
pathophysiological range.  Acute hypoxia rapidly and reversibly decreases macrophage 
NO production.  O2 substrate limitation is responsible for decreased NO production 
during acute hypoxic exposures; no effects were attributable to changes in iNOS protein 
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concentration, iNOS dimerization, NADPH availability, or albeit indirectly, L-arginine 
availability.  The primary differences observed between long term hypoxia and acute 
hypoxia appear to be the additional affects of long term hypoxia on iNOS mRNA and 
protein concentration.  Modification of extracellular L-arginine concentration also rapidly 
and reversibly regulates macrophage NO production.  Acute hypoxia did not appear to 
limit L-arginine availability.  However, the effects of short and long term hypoxia on L-
arginine transport and metabolism requires further investigation.  Both tissue pO2 and L-
arginine concentration may significantly influence macrophage NO production and 
function in vivo.  Further studies of the tissue microenvironment, and its effects on 
macrophage NO production, are required to understand its contribution to the 
pathogenesis of disease.
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APPENDIX:  HYPOXIC CELL CULTURE
Challenges of Hypoxic Cell Culture
Hypoxic cell culture is typically performed using an airtight chamber in which the 
gas phase overlying the media, or headspace gas, is tightly controlled.  There are several 
limitations to this system that limit accurate and precise delivery of O2 to the cells.  When 
the media is not stirred, the poor solubility of O2 in media forces investigators to use a 
long equilibration time to acquire hypoxic conditions (22).  Diffusion of oxygen through 
the media is so slow, that the predicted pO2 calculated based on diffusion alone (i.e. in the 
absence of convection currents) is 0 Torr at 1 mm below the media surface for a 
headspace gas of 40 Torr (22).  Thus, convection currents, due to temperature gradients 
and vibrational changes in the environment, are responsible for the majority of the O2 
delivery to the cell monolayer.  Since these currents depend on the environment, the 
resulting pO2 at the cell monolayer is highly variable within and between cultures, as was 
confirmed in our laboratory (202).  Another common problem experimenters face is that 
many of the materials commonly used for conventional cell culture absorb O2 from room 
air and release substantial amounts into the media during “controlled” anoxia (242). 
These limitations were overcome using the two cell culture systems described below.
Forced Convection Cell Culture
The forced convection cell culture system (Chapter 1, Figure 1) uses 
countercurrent exchange to equilibrate the media with a gas mixture before pumping the 
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media through a capillary tube containing the adherent cells (22).  None of the materials 
used in this system absorb or release O2.  Thus, accurate and precise amounts of O2 can 
be delivered to the cells, and immediate changes between pO2 can be performed.  The 
outflow from this system immediately flows past two ports where various probes can be 
inserted.  In these studies, a NO probe was used to record real-time NO production by the 
cells.  The response time and sensitivity of the probe is such that physiologic changes in 
NO can be detected with as few as 1 X 106 cells in less than 5 seconds from its 
production.  One disadvantage of this system is the limited number of cells (1 X 106), and 
thus limited sample material (protein and RNA) available for analysis.
Thin Film Cell Culture
The thin film cell culture system uses reduced media volume and constant mixing 
to accurately deliver O2 to a cell monolayer (143).  The headspace pO2 is controlled by 
placing the glass dishes or vials into leak proof aluminum chambers, and subjecting them 
to a series of gas exchanges with N2 or O2 to produce the desired headspace pO2 (142-
144, 259).  Chambers are warmed to 37°C and shaken continuously to ensure adequate 
gas exchange between the headspace and the media throughout the experiment.  The pO2 
in the chambers is measured at the end of the incubation period using a polarographic O2 
electrode.  Additionally, EF5, a nitroimidazole, can be used to verify that the cellular pO2 
is equivalent to the headspace pO2 (141, 142).  One disadvantage of this system is the 
slower equilibration time between the headspace pO2 and the O2 tension at the cell 
monolayer (~ 30 minutes).
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